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Abstract
Joseph Scavetta
PREDICTION OF DRUG-DRUG INTERACTION POTENTIAL USING MACHINE
LEARNING APPROACHES
2019-2020
Serhiy Y. Hnatyshyn, Ph.D.
Master of Science in Computer Science

Drug discovery is a long, expensive, and complex, yet crucial process for the
benefit of society. Selecting potential drug candidates requires an understanding of how
well a compound will perform at its task, and more importantly, how safe the compound
will act in patients. A key safety insight is understanding a molecule’s potential for drugdrug interactions. The metabolism of many drugs is mediated by members of the
cytochrome P450 superfamily, notably, the CYP3A4 enzyme. Inhibition of these
enzymes can alter the bioavailability of other drugs, potentially increasing their levels to
toxic amounts. Four models were developed to predict CYP3A4 inhibition: logistic
regression, random forests, support vector machine, and neural network. Two novel
convolutional approaches were explored for data featurization: SMILES string autoextraction and 2D structure auto-extraction. The logistic regression model achieved an
accuracy of 83.2%, the random forests model, 83.4%, the support vector machine model,
81.9%, and the neural network model, 82.3%. Additionally, the model built with SMILE
string auto-extraction had an accuracy of 82.3%, and the model with 2D structure autoextraction, 76.4%. The advantages of the novel featurization methods are their ability to
learn relevant features from compound SMILE strings, eliminating feature engineering.
The developed methodologies can be extended towards predicting any structure-activity
relationship and fitted for other areas of drug discovery and development.
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Chapter 1
Introduction to Drug Discovery
The origins of contemporary drug discovery can be traced back to the 1800s,
when scholars and scientists made many fundamental developments in chemistry: Dmitri
Mendeleev published the periodic table, Svante Arrhenius began theorizing about acids
and bases, and August Kekulé explored aromatic organic molecules, just to name a few
[1]. These advances shook the pharmacology field giving birth to a new area of chemistry
driven pharmacology. Much later, combinatorial chemistry and high-throughput
screening led to a new paradigm in drug discovery: parsing a plethora of data and
compounds to find those that will be successful. However, we can only realize the
significance of the findings when we are able to read, extract, and apply the data.
Unfortunately, data analytics in drug discovery was slow to come as shown by the lack of
improvement in the number of drugs reaching markets [1].
The next evolution in drug discovery, similar to the establishment of chemistry
driven pharmacology, involves an alliance between pharmaceutical disciplines,
bioinformatics, and computer science. Novel developments in computer science research,
especially in the area of machine learning, has led to algorithms that allow scientists to
use historic data for making predictions on new data, while minimizing cost and the
number of errors. Computer aided drug discovery has and will continue to increase the
productivity, speed, and efficiency of drug selection and development [2].
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Drug Discovery Overview
The use of compounds for medicinal purposes has been a vital aspect of human
society. Evidence of drug use dates to the prehistoric period, with written evidence
appearing in ancient Egypt, China, Rome, Greece, and many other civilizations [3]. In
more recent times, pharmaceuticals have increased life expectancy and significantly
reduced the effects of disease and sickness. Diseases that had a devastating effects on
society in the past, such as bacterial infections, smallpox, and tuberculosis, are now
generally non-lethal or have a low-chance to contract [4]. Even diseases that are harder to
control or cure, such as cancer or HIV, have recently began to shift from fatal to chronic
but manageable [4]. In modern society, quick and efficient drug discovery is becoming
more important as the population continues to increase, and people tend to live longer.
Bringing new and improved drugs to the market is important for the health and
safety of society. Though much has improved from the birth of pharmaceutical sciences,
the lifespan of a drug is still lengthy, and the process is costly. On average, it takes over
ten years for a new candidate drug to be approved [5]. Many new candidate compounds
never make it to clinical trials due to a prohibitive cost of failure: from 2015 to 2016 the
median cost of pivotal clinical trial was estimated at $19 million [6]. Less than 1% of
synthesized compounds enter trials [4]. For the drugs that do make it to clinical trials, the
probability of success is also low: the highest three success rates were
•

32.6% for ophthalmology drug candidates,

•

25.5% for cardiovascular drug candidates, and

•

25.2% for infectious disease products;
2

the lowest success rate came in at just 3.4% for oncology trials [7]. Drugs that do succeed
through pre-clinical and clinical trials have an average cost of $2.6 billion per compound
from start to approval [8]. Many candidate compounds will never result in a new
marketed drug as the candidates will fail, while for those that do succeed, both the
duration and costs of the discovery and development are significant.
Following Ator et al.’s overview of drug discovery and development, summarized
in Figure 1, this process starts with target identification where the receptors that the drug
should act upon are selected [4]. Next, the compounds that can act on the target must be
found, which often requires high-throughput screening (HTS) and structure-based drug
design methods [4]. HTS allows us to select compounds that are active against targets.
Compounds from the selection pool are optimized to obtain better drug-like properties
[4]. Optimization is focused on careful examination of candidate drug properties such as
absorption, distribution, metabolism, excretion, and toxicity (ADMET) [9]. After a drug
candidate completes preclinical review and achieves its safety and efficacy goals, it then
can enter clinical development. Clinical development consists of four phases:
•

Phase I trials test the drug candidate for safety on 10 – 100 healthy human
volunteers,

•

Phase II trials continue to test safety while also testing efficacy in 50 – 500 of
those with the targeted disease,

•

Phase III trials test the drug in full-scale with diverse patients and several medical
centers, and

•

Finally, Phase IV trials monitor the drug’s adverse effects post-approval [4].
3

Figure 1. The standard workflow within the drug development pipeline.

Why Drugs Fail
For a drug to get approved, it must enter and succeed in clinical trials. In Phase I
trials most drugs fail due to toxicity. During the Phase II and Phase III trials, drugs often
fail due to efficacy problems, although, toxicity still plays a large role in drug failure
[10]. Because toxicity and efficacy are the two most common causes of drug failure,
ADMET properties are crucial for differentiating between successful drugs and those that
will fail.
Failure during the late stages of the clinical trials is not only very costly in terms
of money, time, and labor, but it is also potentially dangerous to patients participating in
the trials. Clinical trial failures can either be unavoidable due to inadequate scientific
advances or could be prevented through scientific rigor, curiosity, and discipline [11].
Unavoidable failures often lack well performing models due to an insufficient knowledge
4

base of the underlying chemistry and/or biology [11]. Preventable failures are explained
by a lack of optimal study designs, dosages, and safety data [11]. Overall, learning from
earlier mistakes, specifically, collecting, sharing, and analyzing data from both successful
and failed drug tests can help reduce the number of avoidable failures. Furthermore,
developing new models from these data can also help improve the conditions of the
currently unavoidable failures.
Drug Candidate Optimization
The future improvements in the pharmaceutical industry are likely to focus on
methods that will significantly reduce failures in clinical trials. Focusing on an early
evaluation of new drug candidates will help reduce the associated cost and time of the
overall process. Improving pharmacological properties of drug candidates in early stages
will reduce the burden on managing compounds that will eventually fail in clinical trials
[12]. Selecting successful drug candidates is a complex process that requires an
understanding of drug-like properties, relying on the analyses of overwhelming amounts
of data [13]. Various drug candidate selection techniques are discussed below.
Rule-based drug discovery. Rule-based generalizations act as guidelines as to
which physiochemical properties one should expect from a successful drug, as compared
to a less effective drug candidate. Defining common generalizations for the desired
characteristics of drug-like properties is complicated by variations of a drug’s targets and
routes of transmission. The Lipinski's rule of 5 is well known approach to determining
which properties make a successful drug candidate. This approach specifies upper bounds
on molecular properties such as hydrogen bond donors and acceptors, molecular mass,
5

and lipophilicity [14]. While drugs that satisfy Lipinski's rule of 5 are often more
successful than those that do not, many exceptions exist where the model would
disqualify a successful drug and vice-versa [15]. The Lipinski's ruleset focuses on the
absorption properties of a drug, which is only one of many factors that determines a
successful drug candidate. Furthermore, this approach is primarily expressive of
permeability potential; while solubility and dosage may also play a role in absorption
[14]. Also, the bounds apply to oral drugs that do not act as substrates for naturally
occurring transporters [14]. While there are limitations to this approach, the Lipinski’s
rule of 5 is a useful starting point in selecting important drug-like properties in future
drug-prediction models, specifically for absorption models.
Other rule-based methods have been created as an extension to Lipinski's rule of 5
[16]. While the rule-based methods provide a simplified approach for determining drug
success, they are limited in substantial ways. Having a strict cutoff points implies that
these properties are discrete, rather than continuous [17]. Such assumptions can result in
many missed opportunities. Furthermore, these rules are generated only from properties
that successful drugs have in common. However, if the property distributions explored in
successful drug candidates are similar to failed drug candidates, then these properties are
ultimately uninformative [17].
To replace cutoffs with a continuous scale, Bickerton et al. developed the
quantitative estimate of drug-likeness (QED) [18]. This approach performs quite well,
however, it still does not consider whether a property is truly predictive, i.e. has a
different distribution from failed drug candidates. To address both shortcomings of the
6

rule-based approaches, the relative drug likelihood (RDL) can be computed [17]. The
RDL approach performs better than QED as it uses distributions from both successful
drugs candidates and failed drug candidates. This allows RDL to identify properties that
are important to identifying successful drug candidates. Yusof et al. expanded the idea of
RDL and created a new algorithm based on the patient rule induction method (PRIM)
[19]. PRIM differs from RDL by exploring all the properties simultaneously and
identifying redundant properties.
While rule-based methods have improved, they may still lack the ability to
generalize non-linear patterns in the data and may miss important relations. Current
approaches in drug discovery have now shifted towards applying traditional and novel
machine learning algorithms to chemical datasets with a promise of exploring non-linear
patterns within data [2].
Machine learning in drug discovery. There have been numerous models and
commercial software that can predict various ADMET properties for drug candidates
with the help of machine learning techniques [9], [20]. For example, successful drugs
typically have a solubility, denoted as log S, with the values ranging from -1 to -5.
However, finding the solubility of a compound is difficult. Rather than directly
measuring compound’s solubility, the researchers apply machine learning techniques to
construct solubility models using existing data on other compounds. This approach
achieves high accuracy of predicting compound solubility, performing as well as
experimental measurements [21]. Finding favorable ADMET properties is one of the
areas were large sets of data already exist, thus, machine learning can be applied. Other
7

properties, such as a compound’s pharmacokinetics, can also be modeled using machine
learning techniques, but experimentally obtained data sets are less common.
Modeling pharmacokinetic properties of a potential drug is important for
predicting success in clinical trials. Pharmacokinetic parameters can be modeled based on
the potential drug’s physiochemical properties and through experimental assays [20]. For
example, the random forests, a popular machine learning technique, was used to model
the volume of distribution, one of many important pharmacokinetic parameters [20], [22].
Quantitative structure–activity relationship (QSAR) modeling for ligand-based
visual screening, has been benefiting from machine learning techniques. Specifically,
researchers used machine learning algorithms to determine which drugs match a certain
query in a database of potential compounds [23]. QSAR modeling relies on the idea of
structural similarity: compounds with similar structures have similar bioactivities [24]. In
general, QSAR models employ data from the molecular structure of ligands and
examines physiochemical properties, therapeutic activities, and pharmacokinetic
parameters to predict the best molecules for a target [24]. Overall, machine learning
based QSAR modeling for visual screening has advanced many aspects of drug discovery
and development, specifically, by taking advantage of big data to predict complex
biological phenomena [2].
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Chapter 2
Machine Learning Overview
Simulating human intelligence has been an active area of research in mathematics
as far back as the 1700s, when Thomas Bayes developed mathematical fundamentals of
what has become Bayes’ Theorem [25]. Machine learning aims to create algorithms that
can learn from given data to solve problems without specific instructions. Machine
learning is often viewed as a subset of artificial intelligence, though it differs from
common artificial intelligence algorithms in that machine learning emphasizes data rather
than pure domain expertise to complete a task. One important sub-section of machine
learning is a family of methods that devise models to classify or predict a value for an
unknown sample, given a sample of data that has already been classified or has
established values. These methods are commonly categorized as supervised machine
learning [26].
Supervised machine learning employs statistical methods with fast and efficient
algorithms to predict some target function 𝑓: 𝑿 → 𝒚. The target function is unknown, and
may always be unknown, however, using some set of input data 𝑥 ∈ ℝ𝑑 = 𝑿, and some
known output data 𝒚, a function 𝑔 can be created to closely approximate 𝑓. The
combination of input data 𝑿 and output data 𝒚 is called a training set and is denoted as
(𝑥1 , 𝑦1 ), (𝑥2 , 𝑦2 ) … , (𝑥𝑁 , 𝑦𝑁 ). Using the training examples and a set of hypothesis
functions 𝐻, often an infinite set, a learning algorithm can select 𝑔 from 𝐻 that best
approximates 𝑓 [27].

9

Machine Learning Approaches
Linear models. Many of the fundamental machine learning algorithms stems
from the statistical work of linearly modeling relationships between two or more
variables. This type of modeling is often referred to as linear regression, and it was
presented as far back as 1886 by geneticist Francis Galton when he was investigating the
difference in height between parents and children [28]. The overall goal of linear
regression is to predict some dependent variable 𝑦 given some independent variable(s)
𝑥𝑚 using weighted relationships in the form:
𝑦𝑖 = 𝛽0 + 𝛽1 𝑥1 + ⋯ + 𝛽𝑚 𝑥𝑚 + 𝜖

Eq. 1

where 𝛽𝑗 acts as corresponding weights of the variable 𝑥𝑗 , and 𝜖 is the random error [29].
Using known data for the variable(s) 𝑥𝑚 , a prediction of y, denoted as 𝑦̂, can be
computed using a modification of equation 1 as follows:
𝑦̂𝑖 = 𝛽0 + 𝛽1 𝑥1 + ⋯ + 𝛽𝑚 𝑥𝑚

Eq. 2

To find the best predictive function, the weights 𝛽𝑗 can be adjusted to minimize the error
between the predicted 𝑦̂𝑖 and a known 𝑦𝑖 . The least squares method is employed to
minimize the error on each known sample 𝒚 = 𝑦𝑖 ∈ ℝ𝑛 and the samples’ corresponding
prediction from equation 2 [29]. The least squares error can be calculated using the form:
𝑛

∑

(𝑦𝑖 − 𝑦̂𝑖 )2

Eq. 3

𝑖=1

There are two common approaches for minimizing the error: (1) using the normal
equations for a closed form solution and (2) using an iterative method such as gradient
descent. Assuming linear independence between the variables, a unique solution can be
found following the closed form:
10

𝜷 = (𝑿𝑇 𝑿)−1 𝑿𝑇 𝒚

Eq. 4

where 𝜷 is an optimal weight vector given a matrix of independent variables 𝑿 = 𝑥𝑖𝑗 ∈
ℝ𝑚×𝑛 and a vector of corresponding dependent variables 𝒚 = 𝑦𝑖 ∈ ℝ𝑛 [27]. A general
solution to the minimization problem is to use gradient descent, which iteratively adjust
weights and recomputes the global minimum of the error function, until the best solution
is found [30]. Linear regression is a popular statistical method for finding optimal linear
relationships between independent and dependent variables. It is often a good starting
point for solving a prediction task. However, linear regression has limitations as data can
often be non-linear.
A close cousin to linear regression is logistic regression, one of the earliest and
most commonly utilized machine learning algorithms for discrete classification [31]. The
logistic regression learning algorithm approximates a target function. However, rather
than predicting a functional relationship 𝑓(𝑿) = 𝒚, logistic regression models the
probability 𝑃(𝒚|𝑿) of the dependent variables 𝒚 = 𝑦𝑖 ∈ [0,1] belonging to a certain
class, given a set of independent variables 𝑿 = 𝑥𝑖𝑗 ∈ ℝ𝑚×𝑛 [32]. The base form for
logistic regression is similar to linear regression in equation 1. However, logistic
regression applies a soft threshold to equation 1 to achieve the form:
𝑦𝑖 = 𝜃(𝛽0 + 𝛽1 𝑥1 + ⋯ + 𝛽𝑚 𝑥𝑚 + 𝜖)

Eq. 5

where 𝜃 is the logistic function:
𝜃(𝑠) = 𝑒 𝑠 ⁄1 + 𝑒 𝑠

Eq. 6

[27]. A common error measure for logistic regression is maximum likelihood, which can
be minimized in the form:
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𝑛
1
𝑇
∑ ln(1 + 𝑒 −𝑦𝑖 𝜷 𝒙𝑖 )
𝑛
𝑖=1

Eq. 7

Unlike linear regression, logistic regression does not have a closed form solution. Instead,
to minimize error, we can employ gradient descent method which can adjust the logistic
model towards the steepest decrease in error [33]. Overall, logistic regression is
equivalent to linear regression, aside from the addition of the soft threshold logistic
function around the linear model to restrict the functional range to [0,1].
As more variables, or features, are added to linear models, their complexity
increases. This can increase the temptation to fit the function too closely to the limited set
of data points, or in other words, overfit the training data, which may lead to poor
generalization of new data [34]. To mitigate the effects of overfitting, we can use
methods that penalize models for having too large a dependency on any given feature.
This method is often called regularization. Regularization adds another term to the error
function, which penalizes large weights in the model. The two common methods for
2
regularization are ridge (L2) and lasso (L1). Ridge regularization adds the term 𝜆 ∑𝑚
𝑗=1 𝛽𝑗

to the error function, while lasso regularization adds the term 𝜆 ∑𝑚
𝑗=1|𝛽𝑗 | [35]. For
example, with lasso regularization equation 7 can be extended to:
𝑛
𝑚
1
𝑇
∑ ln(1 + 𝑒 −𝑦𝑖 𝜷 𝒙𝑖 ) + 𝜆 ∑ |𝛽𝑗 |
𝑛
𝑖=1
𝑗=1

Eq. 8

The 𝜆 acts as a parameter that controls the complexity of the model; i.e., a low 𝜆 allows
for a more complicated model while a high 𝜆 reduces the complexity. The differences
between the two approaches is that lasso regression allows for the optimal model to drop
terms completely (i.e., setting the feature weights to 0), while ridge regularization does
12

not allow a 0 weight [35]. Traditionally, linear models are often the first sought after
model as they are fast, efficient, and support regularization methods to avoid overfitting.
Though for more complex problems, they may underfit the target function. The field of
machine learning also boasts a large number of other algorithms that are not tied to the
linear domain, which we will discuss next.
Decision trees. Using a set of criteria or decision points, we can split and classify
samples based on the data values. This simple idea is the fundamental concept of decision
trees [32]. The decision tree consists of branch nodes that split paths and leaf nodes that
act as the outcome for a sample. A decision tree is created from top down; determining
which feature of the data will act as the first branch node, and so on. A range of values
can be considered for each branch of a feature node. For example, if some value for the
feature is less than 10, the tree may branch one way, otherwise, it will branch a separate
way. For this reason, ordering features with the most informative features at the top of the
tree is crucial. The more information a feature provides, the more likely it will split the
data into separable classifications down the tree. Feature importance is determined using
one of several feature selection methods.
The first notable feature selection method, introduced by Breiman, Friedman,
Stone, and Olshen in 1984, is the Gini index or Gini impurity. The Gini index can be
interpreted as the estimated probability of misclassifying a random sample using the
selected feature, such that a Gini index of 0 implies a 0% chance that any sample will be
misclassified while a Gini index of 1 implies a 100% chance of misclassification [36].
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Another widely used feature selection method is information gain. Information
gain is based on information entropy, which is defined as the average production of novel
information from randomly selected data. High entropy relates to a low probability of
correctly predicting data, while low entropy relates to a high probability of correctly
predicting information [37]. In short, the best feature to select for branching is the one
that gains the most information, or in other words, select the feature that results in the
greatest reduction of the overall entropy of the prediction task [38].
The strength of decision tree based approaches is accurate classification of data
and also determination of the variable importance [32]. Though decision trees can often
achieve high accuracy on the training data, they are prone to overfitting. This may lead to
a lack of generalization and a decrease in prediction accuracy for new data [39].
Rather than performing classification using only one decision tree, an ensemble of
decision trees can be used to significantly increase the performance of the predictive task
[40]. Adaptive boosting combines multiple “weak learners” (i.e., models with low
predictive effectiveness) into a single unified strong learner (i.e., a model that performs
predictive task well). [41]. Adaptive boosting starts with several decision trees for the
dataset, which may be weak learners. Next, the algorithm adjusts the weights of
misclassified samples and selects a random set of data to create a new decision tree.
Effectively, each new tree is dependent on the errors of the earlier trees. Along with this,
each tree stores a weight of importance towards the final collective decision based on
how well that individual tree performed.
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Another popular ensemble method is bootstrap aggregation, or bagging. The
bagging method constructs independent decision trees, each created from a bootstrapped
sub-sample of the original dataset. This approach does sampling with replacement which
allows duplication of observations [40]. The dataset is split into bootstrap samples many
times, so that many varying trees are created. The resulting decision trees collectively
perform prediction task by selecting the majority answer.
The random forests approach works similarly to the bagging method by creating
multiple decision trees, however, created trees differ in their feature sub-space. Each tree
is created by sampling the entire training set but with a randomly selected subset of
available features [39]. Again, the consensus among individual trees is used to make the
final prediction. In practice, the random forests approach relies on a combination of
bagging with random feature sub-spacing [42]. Decision trees used collectively as
random forests often provide some of the best average performance and are less sensitive
to overfitting as compared to other methodologies [43], [44].
Support vector machine. The support vector machine (SVM) is a versatile
machine learning approach that allows classification of linearly separable as well as nonlinear data. SVMs are similar to linear models, in the sense that they try to fit a line that
can split data into two classes. However, the SVM approach has the advantage of finding
the optimal hyperplane which maximizes the distance of the data on both sides [45]. This
approach allows for more robustness in generalizing towards new data after training, as
there is more leeway for the data to trend towards hyperplane without crossing the class
boundary. The SMV approach provides model stability by finding the optimal solution
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every time, yielding consistent results for the same data [45]. This consistency makes
support vector machine appealing for practical use. If data is not linearly separable, then
the non-linear data can be projected into a high dimension, potentially allowing the data
to become linearly separable [45]. SVM’s versatility of handling linear and non-linear
data makes it a practical solution to many varying prediction tasks that may differ widely
in complexity of the data.
Artificial neural network. Recently, artificial neural networks (ANN) gained
popularity and have reached the forefront of machine learning research and technology.
Neural networks are based on the perceptron, a fundamental learning algorithm that was
modeled from the biological neuron to learn a task [46]. A basic neural network consists
of multiple layers of perceptrons, referred to as neurons, which are linked together in
numerous ways to produce complex relationships from the input to the output data.
Though research on neural networks was stagnant following the criticism of machine
learning by Minsky and Papert in their book Perceptrons: an introduction to
computational geometry [47], ANNs returned to the forefront with the creation of backpropagation methods, an increase in computational power, and availability of modern
computers. Back-propagation is a technique that allows for the connections, or weights,
between one neuron and another to be adjusted towards a global minimization of the
output error for many neurons and the true output [48]. Using back-propagation, ANN
models consisting of hundreds or more neurons have their connections adjusted in a way
that the overall model can take an input and accurately output a response in a short
amount of time and with little human effort. The greatest advantage of ANNs is the
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possibility of modeling complicated non-linear relationships, as neural networks can
often find hidden relationships between data that are difficult to detect.
In recent years, many machine-learning practitioners have used the term deep
learning to describe a more complex neural networks that have many hidden layers. Deep
learning succeeds at modeling even the most complicated relationships than a smaller
standard ANN cannot achieve. For example, deep learning allowed computers to learn to
play and to defeat professionals at the game of Go [49]. Convolutional neural networks
(CNN) and recurrent neural networks (RNN) are examples of deep learning artificial
neural networks. Similar to a standard ANN, a CNN has multiple layers of neurons.
However, CNNs employ layers of convolution kernels. In contrast to a fully connected
ANN that connects all neurons within two adjacent layers, convolution kernels only look
at a sub-sample of input neurons to generate an output [50]. Overall, convolutional neural
networks work very well with image recognition. The convolution kernels can learn
image filters without extensive feature-engineering on the input, and with less
computational overhead as compared to a fully connected network.
Recurrent neural networks differ from typical feed-forward networks in creation
of connections across neurons based on time or sequence. This adjustment allows for a
dynamic learning process where the neural network can remember earlier data in a
sequence while training the next step in a sequence. Because of their notion of memory,
recurrent networks can work well for sequential inputs such as text or speech [51]. Deep
networks have many more variations that are well suited to specific problems.
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Machine Learning Tools
The data that is being analyzed is often not perfect and may suffer from such
deficiencies as missing values, major differences in unit variance, unbalanced classes, or
an overwhelming number of features. One must also consider how the models will be
evaluated. Although the end goal is to minimize error in the models, the process of
determining and comparing errors across models is not resolute. Finally, additional
information about models such as the features that were most important or how changes
in the features affect the models’ predictions may be of interest.
Data preprocessing. It is uncommon for the data to be collected in a perfect
form. Preprocessing is often employed to handle inconsistencies and issues within the
collected datasets. There is no simple solution for handling all issues with missing data.
Approaches to handle missing data may include removing the samples or features that
have missing data or filling in the missing data with some estimated value. If a large
portion of data is unavailable, or specific samples or features contain a significant amount
of missing data, it may be worth removing samples or features altogether. However, to
avoid removing useful data, missing data can be estimated by taking the mean of the
feature values, or the mode, if the feature is categorical. Of course, a mixture of both
removing and imputing the values can be used as well.
During the data preprocessing phase, the researchers should also consider whether
the features should be standardized or normalized. It is possible that one feature may
unfairly bias the importance of other features. While in some cases such side effect could
be desirable, it is often the result of inconsistent selection of the feature units. This issue
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is often resolved by normalizing all features to be between 0 and 1 or standardizing the
features so that they all have a mean of 0 and a standard deviation of 1.
Another problem that is often ignored is the lack of class balance in the dataset.
For example, if a dataset contains 90% of class A samples then the model can be 90%
accurate by always predicting that a sample belongs to class A. This issue can be solved
by adjusting the accuracy or error metric, but sometimes it is better to address it at the
data level instead. There are two main approaches to balancing a dataset: (1) removing
from the over-sampled class and (2) adding to the under-sampled class. Removing from
the over-sampled class can be as trivial as randomly selecting and removing samples
within that class. However, this method risks losing important information from the
dataset.
Adding data to an under-sampled class could be achieved by either sampling with
replacement or by generating synthetic data points. Sampling with replacement simply
duplicates randomly selected samples of under-sampled class. The Synthetic Minority
Over-Sampling Technique (SMOTE) is a method for generating synthetic data points.
This approach randomly creates samples with features that would exist within the
boundaries of the true class data [52].
Sometimes, there are too many features present in a given dataset. An
overabundance of bad features or many correlated features could hurt the performance of
a model by allowing it to learn based on misguided data. It can also lead to a significant
slowdown of the algorithm. To mitigate the problem of too many features, the
preprocessing can employ univariate feature selection or principal component analysis
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(PCA). The univariate feature selection approach selects the 𝑛 best features based on
certain statistical test or based on the amount of variance. The advantage to this approach
is that the values of the remaining features will not change, those considered
uninformative will simply be removed. However, eliminating features may lead to losing
useful information. PCA is more robust against losing information as it transforms the
original features into a few (𝑛) linear combinations of the features (principal
components) with the highest amount of variance [53]. By using orthogonal
transformations, PCA can convert correlated features into linearly uncorrelated principal
components. Overall, the intentions of modeling and the amount of redundancy in the
dataset may decide which, if any, approaches are taken.
Metrics and workflows. Model accuracy is an important metric for comparison
of model performance. Assume that the given dataset consists of two classes: class
positive and class negative. In this example, summarized in figure 2, the elements can be
classified as follows:
•

True positive (𝑇𝑃) - number of positive elements classified as positive,

•

False negative (𝐹𝑁) - number of positive elements classified as negative,

•

False Positive (𝐹𝑃) - number of negative elements classified as positive,
and

•

True Negative (𝑇𝑁) - number of negative elements classified as negative.
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Figure 2. The possible outcomes for a binary classification prediction.

Using the above notation, we can define model accuracy as
(𝑇𝑃 + 𝑇𝑁)⁄(𝑇𝑃 + 𝐹𝑁 + 𝐹𝑃 + 𝑇𝑁). The model accuracy specifies the proportion of
predictions that are correct. Other considered evaluation metrics are model’s precision
𝑇𝑃⁄(𝑇𝑃 + 𝐹𝑃), recall 𝑇𝑃⁄(𝑇𝑃 + 𝐹𝑁), false discovery rate 𝐹𝑃 ⁄(𝐹𝑃 + 𝑇𝑃) and/or an F1
score 2𝑇𝑃⁄(2𝑇𝑃 + 𝐹𝑃 + 𝐹𝑁). Model accuracy, along with other metrics, may help truly
understand how well a model is performing. For example, the F1 score can be thought of
as the harmonic mean of the model’s precision and recall, creating a more robust metric.
The usage of the overall dataset in training and testing models has an important
impact on the observed performance metrics. The training and testing models can be
viewed as how well the model is able to train on a given dataset and how well the model
is able to classify data it has never seen, respectively. Model bias defines how well the
model is trained: a high bias means it did not train well to the dataset and a low bias
means it has trained well to the dataset. Model variance explains how well the model
performs a classification task: high variance means new data is not classified well and
low variance means new data is classified well. To determine model bias, we can simply
evaluate the model on the training data. To determine model variance, we must use a
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dataset that the model was not trained on. To compute model’s bias and variance the
dataset could be randomly split into two subsets, creating a training set and a testing set.
The cross-validation approach trains and tests the model while rotating the data in
the training and testing set such that all data will be used in the testing set once. Crossvalidation is typically considered a better approach as it allows for a statistical
comparison between models and gives a way to find performance anomalies on specific
portions of the dataset. Please note that data-preprocessing should be computed only on
the testing set and the results should be projected onto the testing set. For example, if
missing data is estimated, they should only be estimated using data from the training set,
otherwise, information may be leaked into the testing set. Information leaking can bias
the scoring functions to overestimate a model’s performance.
Model analysis. After the best performing model is selected, the details of a
model’s functionality may be of interest. Some model details that could be useful are the
weighted importance of each variable, or how the different values a variable could obtain
influence model predictions. Investigating variable or feature importance is trivial when
working with linear based models because the absolute value of the weights associated
with the features gives a clear indication as to which features change the prediction more
heavily than others. The same is true for decision trees, where the Gini index or the
information gain can show how important a feature is within the tree. To understand how
a feature’s value influences a model’s sensitivity, partial dependence of various features
can be plotted and analyzed. The researchers observe how the output changes across the
feature domain when the model is fed the average values of all other features, or one
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feature value is changed from certain minimum and maximum. The unified framework,
SHAP (SHapley Additive exPlanations) assigns each feature an importance value for a
given prediction. This is a model agnostic approach for performing exploration
techniques [54], which allow us to better understand the model rather than leaving it a
black box.
Predictive Models
There are many modeling approaches for predicting and evaluating potential drug
activities [55]. Using empirical data, one could take a modeling approach that does not
rely on fundamental knowledge of the system. This can be reliable as many drug
phenomena are complex and not yet well understood. Two common empirical modeling
methods are ligand-based, and target-based approaches [55]. In ligand-based approaches,
shown in Figure 3, known active and inactive compounds can be used to detect important
structural features for the activity in question. In target-based approaches, the structural
features of the enzyme or protein in question can be used to detect potential ligand
interactions. Both methods can benefit from machine learning techniques. Target-based
approaches can use regression methods to learn and model various enzyme-ligand
docking conformations. Ligand-based approaches can use regression or classification
techniques to predict a ligand’s activity towards the enzyme or the phenomena being
modeled.
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Figure 3. Ligand-based modeling approaches.
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Chapter 3
Biological Role of Cytochrome P450 Enzymes
Cytochromes are an important class of proteins for all biological species.
Containing heme as a cofactor, they are involved in electron transport reactions and act as
enzymes in reduction and oxidation reactions. Cytochrome proteins were first discovered
in 1884 [56], but didn’t receive the cytochrome name until the 1920s [57]. There are four
major types of cytochrome proteins, which can be distinguished by analytical chemistry
techniques. Various spectroscopy methods enable analyzing the exact structure of the
heme group, analyzing inhibitor sensitivity, and analyzing reduction potential [58]. This
chapter focuses on the cytochrome P450 superfamily of enzymes, which named after the
characteristic peak formed by absorbance of light at wavelengths near 450 nm, when the
heme iron is reduced to carbon monoxide. These enzymes, specifically the 3A4 variant,
play an important role in oxidative metabolism and are primarily involved in
steroidogenesis and detoxification [58].
The cytochrome P450 superfamily are categorized as cytochromes that act as
monooxygenases, reducing oxygen to a hydroxyl group for incorporation into substrates
[59]. Cytochrome P450 enzymes are found in all domains of life and consist of more than
2000 distinct proteins across different species [60]. There has been a total of 57 human
genes described within the P450 superfamily with substrates including sterols, fatty acids,
eicosanoids, vitamins, and xenobiotics [61]. The oxidation of xenobiotics is particularly
important for reducing toxicity that is involved with the incorporation of foreign
compounds, which may often be pharmaceuticals. The metabolism, of an estimated 75%
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of drugs, is mediated by P450 enzymes, emphasizing the importance of this family of
proteins in drug design [61]. According to their intracellular localization, P450 enzymes
may be classified into: 1) microsomal cytochrome P450, which are present mainly in the
microsomes of liver cells and represents about 14% of the microsomal fraction of liver
cells or 2) mitochondrial cytochrome P450, which are present in mitochondria of many
tissues but is particularly abundant in the liver and steroidogenic tissues such as adrenal
cortex, testis, ovary, placenta, and kidney.
Metabolic Reactions Mediated by CYP3A
The P450 protein superfamily can be further broken down into families,
subfamilies, and finally the specific gene products. The most common and the most
versatile member of the cytochrome P450 family of oxidizing enzymes is CYP3A4. Like
all other members of this family CYP3A4 is a hemoprotein which is involved in drug
metabolism. In humans, the CYP3A4 protein is encoded by the CYP3A4 gene [62]. This
gene is part of a cluster of Cytochrome P450 genes and, as visible in Figure 4, is
positioned at chromosome 7q22.1 [63].
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Figure 4. Human chromosome 7 with cytogenetic bands displayed.

According to Wienkers at al [64] the bulk of the metabolism of known drugs in
humans is mediated by cytochrome P450 (CYP) enzymes. Among those, the majority of
drug oxidations (46%) were carried out by members of the CYP3A family. CYP3A
catalyze many reactions involved in drug metabolism as well as in synthesis of
cholesterol, steroids, and other lipids components. Enzymes of CYP3A family mainly
found in the liver and in the intestine. Their role is oxidation of small foreign organic
molecules (xenobiotics), such as toxins or drugs, so that they can be removed from the
body. This makes CYP3A enzymes remarkably important in drug design and
pharmaceutical research.
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The CYP3A subfamily consists of 4 genes: CYP3A4, CYP3A5, CYP3A7, and
CYP3A43. Of the four, CYP3A4 tends to have the highest expression and the greatest
affinity for metabolizing pharmaceutical drugs [65]. CYP3A4 has a large and flexible
active site, and can bind with many large lipophilic compounds, allowing for substrates
like immunosuppressants, antibiotics, antidepressants, opioids, and many others [65]. The
CYP3A4 protein is an important enzyme in first-pass metabolism, where some amount of
a drug may be metabolized before entering systemic circulation [66]. A snapshot of the
KEGG entry for CYP3A4 is shown in Figure 5. A sample oxidative reaction catalyzed by
CYP3A4 is shown in Figure 6, where a xenobiotic molecule binds with oxygen, creating
a less toxic drug and/or a drug that is easier to metabolize downstream.
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Figure 5. KEGG entry for the CYP3A4 gene.
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Figure 6. Oxidation reaction catalyzed by CYP3A4. Obtained from KEGG R05727.

Potential for Drug-Drug Interactions
The role of metabolic reactions catalyzed by CYPs is to transform the xenobiotic
substances to harmless and excretable metabolites [55]. Issues arise in the situation when
xenobiotic substances are transformed into a toxic metabolite or the speed of metabolic
clearances is significantly altered. The reliance on P450 enzymes to oxidize and facilitate
the removal of dugs opens the potential for issues in drug metabolism. Two major issues
in drug metabolism are 1) the bioavailability of a drug, i.e., how quickly the drug is
metabolized and eliminated, and 2) the accumulation of the drug in the system, which
could cause toxic side effects. Issues in bioavailability may arise if the P450 enzymes are
induced by another drug, while issues in drug toxicity could occur if the P450 enzymes
are inhibited by another drug. The inhibition of P450 enzymes is often the cause of many
adverse drug reaction as these drugs are metabolized at slower rates and can begin to
accumulate at levels that are toxic [61]. The ability for one drug to affect another drug’s
metabolism is referred to as a drug-drug interaction. This interaction is often linked to the
inhibition or induction of a P450 enzyme.
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Interferences with the Action of the CYP3A4 Enzyme
While many drugs are metabolized by CYP3A4 mediated reactions, there are also
some drugs which are activated by the enzyme. Some substances, such as grapefruit juice
and some drugs, interfere with the action of CYP3A4. These substances will therefore
either amplify or weaken the action of the drugs that are modified by CYP3A4,
potentially causing them to exceed the minimum toxicity levels and create adverse side
effects. Inhibition can happen in one of three ways, 1) competitive, in which the inhibitor
competes with the substrate for the active site within the enzyme, 2) non-competitive,
where the inhibitor reduces the activity of the enzyme, and 3) mechanism-based, where
the inhibitor is metabolized into a reactive group that can form an irreversible bond with
the enzyme. A well reported case of CYP3A4 inhibition was discovered by researchers
who noticed an increase in bioavailability of many drugs in patients after consuming
grapefruit juice. This effect is due to bergamottin, a furanocoumarin, found within
grapefruit that acts as a mechanism-based inhibitor of CYP3A4 [67].
Screening for CYP3A4 Inhibitors
Understanding a drug’s potential to inhibit CYP3A4 is a common step in drug
development; many in vitro and some in vivo assays are conducted on potential drugs to
determine if they have any inhibitory ability. The potential for a drug to inhibit CYP3A4
can be assessed in vitro by using a probe substrate. The probe must be a compound that is
metabolized by the CYP3A4 enzyme. A commonly used probe is midazolam, a known
substrate of CYP3A4, which performs similarly in vitro and in vivo [68]. The screening
process works as follows. The probe is placed in a mixture of microsomes that contain
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the CYP3A4 enzyme and other drugs that are being assessed. If the drug inhibits
CYP3A4, the probe can no longer be metabolized at its standard rate. This will result in
lower level of metabolites, which can be measured to determine if inhibition was taking
place. To increase throughput, CYP3A4 inhibition assays typically use either a
fluorescent probe or Liquid Chromatography Mass Spectrometry (LC-MS/MS) to
monitor the rate of probe metabolism [64]. Recently, there has also been an effort in
predicting CYP3A4 inhibition in silico, which could save time and resources in the
lengthy and expensive drug development pipeline.
Kinetics of CYP3A Meditated Reactions
The kinetics of drug metabolism can be summarized by few computed values:
Michaelis-Menten constants (Km), maximal velocities (Vmax), and intrinsic clearance
(CLint, Vmax/Km). Similarly, protein inhibition and kinetics can be understood through
values such as the inhibition constant (Ki) and the inhibitory concentrations (IC50). While
this manuscript focuses on CYP3A4, many compounds that are substrates of CYP3A4
can also be metabolized by CYP3A5 [69]. The speed of metabolism varies by compound
and drug class. For example, antifungals on average have a lower CLint than antivirals,
with an exception for Itraconazole [69]. The strength of inhibition and induction also
varies by compound, a list of compounds with varying degrees of inhibition or induction
strength are displayed in Table 1.
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Table 1
Known Inhibitors and Inducers for CYP3A4
Compound Name

Strength

Type

Boceprevir

Strong

Inhibitor

Cobicistat

Strong

Inhibitor

Danoprevir and Ritonavir

Strong

Inhibitor

Elvitegravir and Ritonavir

Strong

Inhibitor

Grapefruit Juice

Strong

Inhibitor

Indinavir and Ritonavir

Strong

Inhibitor

Itraconazole

Strong

Inhibitor

Ketoconazole

Strong

Inhibitor

Lopinavir and Ritonavir

Strong

Inhibitor

Posaconazole

Strong

Inhibitor

Ritonavir

Strong

Inhibitor

Saquinavir and Ritonavir

Strong

Inhibitor

Telaprevir

Strong

Inhibitor

Tipranavir and Ritonavir

Strong

Inhibitor

Telithromycin

Strong

Inhibitor

Troleandomycin

Strong

Inhibitor

Voriconazole

Strong

Inhibitor

Clarithromycin

Strong

Inhibitor

Idelalisib

Strong

Inhibitor

Nefazodone

Strong

Inhibitor

Nelfinavir

Strong

Inhibitor

Aprepitant

Moderate

Inhibitor

Ciprofloxacin

Moderate

Inhibitor

Conivaptan

Moderate

Inhibitor

Crizotinib

Moderate

Inhibitor

Cyclosporine

Moderate

Inhibitor

Diltiazem

Moderate

Inhibitor

Dronedarone

Moderate

Inhibitor

Erythromycin

Moderate

Inhibitor

Fluconazole

Moderate

Inhibitor

Fluvoxamine

Moderate

Inhibitor

Imatinib

Moderate

Inhibitor

Tofisopam

Moderate

Inhibitor

Verapamil

Moderate

Inhibitor

Chlorzoxazone

Weak

Inhibitor

Cilostazol

Weak

Inhibitor

Cimetidine

Weak

Inhibitor

Clotrimazole

Weak

Inhibitor
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Table 1 (continued)
Compound Name

Strength

Type

Fosaprepitant

Weak

Inhibitor

Istradefylline

Weak

Inhibitor

Ivacaftor

Weak

Inhibitor

Lomitapide

Weak

Inhibitor

Ranitidine

Weak

Inhibitor

Ranolazine

Weak

Inhibitor

Ticagrelor

Weak

Inhibitor

Apalutamide

Strong

Inducer

Carbamazepine

Strong

Inducer

Enzalutamide

Strong

Inducer

Mitotane

Strong

Inducer

Phenytoin

Strong

Inducer

Rifampin

Strong

Inducer

St. John’s Wort

Strong

Inducer

Bosentan

Moderate

Inducer

Efavirenz

Moderate

Inducer

Etravirine

Moderate

Inducer

Phenobarbital

Moderate

Inducer

Primidone

Moderate

Inducer

Armodafinil

Weak

Inducer

Modafinil

Weak

Inducer

Rufinamide

Weak

Inducer

Bioanalytical Methods to Study CYP3A Mediated Metabolism
The bioanalytical approaches for metabolism studies can be classified into three
main categories: 1) metabolite profiling and identification, which includes
biotransformation and structural analysis both in vitro and in vivo; 2) metabolic stability,
which includes profiling the kinetics both in vitro and in vivo, and 3) identification of
rate-limiting CYP enzymes in vitro only. The third approach is often used for drug
interaction studies which examine the influence of a drug substrate on CYP activity: 1)
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CYP inhibition: single substrate or cocktail study in microsomes or in hepatocytes, and 2)
CYP induction: nuclear receptor activation or cocktail studies in hepatocytes [70]–[74].
Traditional in vitro CYP450 inhibition assays typically target six isoforms of
P450: CYP1A2, 2C9, 2C19, 2D6, 3A4, and 3A5, which are known to metabolize more
than 90% of drugs. There are two major types of assays: 1) single-substrate assays using
known P450 inhibitors and licorice root extract and 2) cocktail assays, also known as Nin-one assays [75].
Single-substrate assay typically evaluates the inhibition of a drug on one P450
isoform at a time. The cocktail inhibition assays can simultaneously evaluate the
inhibition effects of drugs on up to 12 CYP450 isoforms. While cocktail assays are much
more efficient than traditional single probe substrate approaches, they still have some
disadvantages. They are much more complex and require significant investment into an
assay’s parameter optimization. Cocktail assay parameter optimization includes selection
of enzyme protein concentration, minimization of probe substrate interactions,
minimization of solvent effects, complicated detection of probe substrates and usage of a
fast and sensitive ultrahigh pressure liquid chromatography (UHPLC) – tandem mass
spectrometry (MS/MS) quantitative instrumentation. Typical experimental procedure
requires potassium phosphate buffer (100 ml, 0.1 M, pH 7.4) containing 1.3 mM
NADPH, 0.2 mg/ml human liver microsomes, and a cocktail of 10 probe substrates
including midazolam, which is used for testing CYP3A4 activity [75]. Such experimental
procedures are expensive and time-consuming, thus the development of accurate
theoretical models to predict CYP450 activity is highly desirable.
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In Silico Prediction of CYP–Ligand Interactions
In silico models to predict characteristics of CYP–ligand interactions attempt to
link the structure and properties of ligand with the readouts from CYP mediated
metabolic transformations obtained during in vitro experiments. Such models enable the
researchers to exploit experimentally derived data and fill the gaps in understanding of
(1) the affinity of ligand binding to specific CYPs;
(2) predicting sites of metabolism;
(3) prediction of inhibition characteristics of test molecules [55].
Inhibition Model Review
The task of predicting CYP3A4 inhibition in silico has been examined before with
the help of various theoretical models. A summary of these studies is presented in Table
2. In 2011, Cheng et al. was able to develop a model based on the support vector machine
approach, which achieved a cross-validation accuracy of 0.775 [76]. The models utilized
MACCS fingerprints determined from the compound structures. In addition, Sun et al.
achieved a cross-validation accuracy of 0.811, also using a support vector machine model
in 2011. The primary difference between these approaches was in the feature set and the
use of custom atom type descriptors [77]. More recently, in 2018, Li et al. used an auto
encoder deep neural network that was able to achieve a cross-validation accuracy of
0.850. This study used a set of features generated using the PaDEL software in addition
to the compounds’ PubChem fingerprints [78]. In 2019, Wu et al. extended on previous
work and developed a new XGBoost approach that achieved a cross-validation accuracy
of 0.860 [79].
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Table 2
CYP3A4 Inhibitor Prediction Models in Literature
Authors

Date

Model

Accuracy

# Training

Wu et al.

2019

XGBoost

0.860

(3070, 5985)

Wu et al.

2019

Gradient Boosting DT

0.851

(3070, 5985)

Wu et al.

2019

Deep NN

0.839

(3070, 5985)

Wu et al.

2019

Convolutional NN

0.833

(3070, 5985)

Wu et al.

2019

Random Forests

0.828

(3070, 5985)

Li et al..

2018

Multitask AE-DNN

0.850

(3070, 5985)

Li et al.

2018

Singletask AE-DNN

0.845

(3070, 5985)

Lee et al.

2017

Laplacian Naïve Bayes

0.799

(1193, 2221)

VolSurf+

Su et al.

2015

Support Vector Machine

0.756

(5177, 7456)

PaDEL3D, Mold

Su et al.

2015

C5.0 Decision Tree

0.733

(5177, 7456)

PaDEL3D, Mold

Sun et al.

2011

Support Vector Machine

0.811

(2334, 4466)

Custom Atom types

Cheng et al.

2011

Support Vector Machine

0.775

(4637, 6899)

MACCS

Cheng et al.

2011

Stack: SVM; K-NN

0.767

(4637, 6899)

MACCS

Cheng et al.

2011

Stack: SVM; Naïve Bayes

0.752

(4637, 6899)

FP4
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Feature Set
PaDEL1&2D,
PubChem FP
PaDEL1&2D,
PubChem FP
PaDEL1&2D,
PubChem FP
PaDEL1&2D,
PubChem FP
PaDEL1&2D,
PubChem FP
PaDEL1&2D,
PubChem FP
PaDEL1&2D,
PubChem FP

Chapter 4
Representation, Modeling, and Featurization of Chemical Compounds
Much of chemical exploration and research relies on computational tools and
techniques to represent and study compound structures. However, it is not trivial to
efficiently represent a compound in its entirety. At a basic level, we can view a
compound as a graph representing atoms as nodes and bonds as vertices. However, the
graph must ensure that the differences in compound configuration are also clearly
distinguished. For example, features such as single, double, triple, and ionic bonds, the
stereochemistry of an atom, or aromaticity could be difficult to represent. Creating a
graph-based representation that covers all of these aspects is not necessarily impossible.
In fact, many of these features are often used to visualize compounds [80]. However,
existing representations often lack the ability to store structural information or to gather
complex information from of a compound in an efficient manner. As summarized in
Table 3 there are other techniques that can be used to represent compounds, such as the
simplified molecular-input line-entry system (SMILES), generating molecular
fingerprints, or simply using their molecular descriptors. These techniques allow us to
describe complex compounds numerically, so that a computer can easily and efficiently
process them.
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Table 3
Featurization Methods Useful for Predictive Modeling in Drug Discovery
Featurization

Type

Description

Ref

SMILE

String

Alphanumeric characters representing the 2D structure

[2]

MACCS

Fingerprint

960 or 166 structural keys for important substructures

[5]

PubChem FP

Fingerprint

881 structural keys used by the PubChem database

[6]

ExtendedConnectivity

Fingerprint

Sets bits based on the structure in a radius of focused atoms

[7]

PaDEL

Descriptor

Calculate 797 chemical features including 1D, 2D, and 3D

[8]

Mordred

Descriptor

Calculate more than 1800 2D and 3D descriptors

[9]

Simplified Molecular-Input Line-Entry System (SMILES)
The simplified molecular-input line-entry system (SMILES) is a widely used
representation of compounds. As its name suggests, this method attempts to model a
particular compound using a single line of characters. SMILES relies on a set of parsing
rules that allow for an unambiguous reconstruction of a compound’s structure. This
approach was first introduced in the 1980s [81]. While currently there are other formats,
the fundamentals of a SMILE compound representation as a string remain unchanged.
For example, atoms are denoted by an uppercase character abbreviation, e.g., carbon is
represented as C, nitrogen as N, fluorine as F, chlorine as Cl, etc. Atoms can also be
extended to include their charge, as applicable. For instance, a hydroxide may be depicted
as [OH-] to indicated that the OH group contains a formal negative charge and a
titanium(IV) atom may be depicted as [Ti+4] to indicate a formal positive charge of 4. To
represent bonds, the characters “.”, “-”, “=”, “#”, “$”, “:”, can be used for a non-bond,
single bond, double bond, triple bond, quadruple bond, and aromatic bond. Bond
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stereochemistry can be denoted using “/” and “\” characters which represent single bonds
connected to a double bonded pair of atoms. For example, F/C=C/F shows the trans
configuration while F/C=C\F represents the cis configuration. Often, standard single
bonds are assumed and omitted, thus, it is rare to see “-” within a SMILE string.
To store ring structures in a SMILE string, one arbitrary bond within the ring is
broken and an integer value is placed instead. At the end of the ring, the integer value is
repeated to show that the ring has closed. For example, cyclohexane, a ring of 6 single
bonded carbons, would be represented as C1CCCCC1. Integers can be incremented to
demonstration additional rings in the compound. Aromatic rings can be shown in a
multitude of styles. However, the common syntax is to convert the atom symbols into
lowercase characters. For example, using this approach, benzene, a 6-carbon aromatic
ring, can be shown as c1ccccc1.
SMILE format also allows representing multiple branching points using
parenthesis. Specifically, the atom where the branch starts is followed by the branch
portion of the compound surrounded by an open and close parenthesis. For example,
isopropyl alcohol is denoted by CC(C)O, indicating that the third carbon branches off of
the second and is not bonded to the oxygen. Branch bonds that must be shown, such as a
double bond, are denoted within the parentheses. For example, acetone is represented as
CC(=O)C to indicate that the oxygen is double bonded to the second carbon, while the
third carbon is also bonded to the second carbon rather than the oxygen.
A final consideration in the structural representation of a compound is the chiral
configuration of a tetrahedral carbon, where the positional order of the four bonds may be
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chemically important. There are a several ways to represent chirality. It is often denoted
by a clockwise or counter-clockwise bond order with either @ (counter-clockwise) or
@@ (clockwise) characters in a SMILE string. For example, the amino acid L-alanine
and D-alanine are represented as N[C@@H](C)C(=O)O and N[C@H](C)C(=O)O,
respectively.
CANGEN was the first standard algorithm for creating canonical SMILE strings
to ensure that each compound has a unique SMILE representation [82]. Recently new
algorithms that achieve better results were developed. For example, the public chemical
database ChEMBL uses Accelrys's Pipeline Pilot software to generate their canonical
SMILE strings [83]. Overall, a standardized canonical SMILE algorithm can ensure
uniqueness of compound representation, which is vital when searching for specific
compounds, similar compounds, or compounds that contain a particular sub-structure.
Canonical SMILE strings can also provide a normalized structure placement when
mining structural information from many SMILE strings.
Molecular Fingerprints
Another approach to representing a compound, especially for similarity scoring or
for data mining, is molecular fingerprints. The essence of a fingerprint is that the
compound is represented as a variable length string of bits. Each bit identifies the
presence or lack of certain piece of information from of the compound. There are many
approaches to generating fingerprints, notably, substructure keys-based, topological or
path-based, and circular [84].
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Substructure keys-based fingerprints are based on the idea of chemical motifs or
functional groups. Each bit in the compound’s notation indicates the presence or absence
of a given substructure. This can typically be done with SMARTS patterns, where a
SMILE string is parsed for a particular character sequence, similar to regular expressions.
Examples of substructure keys-based fingerprints include MACCS fingerprints, which
has 960 or 166 structural keys for important and popular substructures in drug discovery
[85], and PubChem fingerprints, which contains 881 structural keys used by the
PubChem database for similarity searching [86]. Structure based fingerprints are
important for tasks that rely on the presence or absence of particular functional groups in
a compound, such as, filtering compounds that may be reactive based on the presence of
one or more reactive chemical motifs.
Topological or path-based fingerprints do not rely on predefined keys and a set
number of bit positions, instead, they parse molecular fragments along bond paths. While
moving along a bond path, these methods hash the path into a new bit position. The
location of that bit within the bit string is determined by the hashing function. These
methods can be customized to generate a string of any number of bits by adjusting the
hashing function. An example of topological fingerprints is the Daylight fingerprints that
contain 2048 bits. The downside to this approach is a possibility of collision, which may
place different substructures at the same bit position, possibly losing information.
Circular fingerprints, also called extended-connectivity fingerprints (ECFPs), are
similar to topological fingerprints in that they hash the chemical structures. However,
bond paths are not traveled down the molecule, instead, the structure within a given
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radius of an atom is searched. ECFPs have the advantage that they can be calculated
quickly and can represent any number of molecular features, while also capturing
stereochemical information [87]. While the bits may be harder to utilize in substructure
searching, this approach could provide much more information about a compound for
data mining applications.
Molecular fingerprints can be an efficient and highly versatile representation of
compounds, allowing for computed similarity scores between compounds, searching
databases with substructure queries, extracting chemical and structural information from
compounds, and transforming compounds into useful features for data mining pipelines.
Many of the fingerprint techniques can be used together with the SMILES representation
as both approaches have their advantages. Therefore, the fingerprints approach is not
necessarily a replacement of SMILE strings.
Molecular Descriptors
Representing a compound as a set of molecular descriptors is another approach
that computes chemically relevant data. This approach can represent complex features
such as a molecule’s solubility or acidic properties and often formats features in ways
that are easier to interpret compared to fingerprints. Molecular descriptors could range
from something as simple as a molecular weight to structural information such as the
molecular surface area and electrostatic properties such as polar surface area. There are
many packages that can calculate numerous molecular features for a given compound. In
this work we will focus on the following two popular software packages: PaDELDescriptor and Mordred.
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PaDEL-Descriptor is an open source software that can generate 797 chemical
features including 1D, 2D, and 3D descriptors [88]. The types of descriptors calculated
by PaDEL include constitutional, topological, geometric, electrostatic, hydrophobic,
steric, and quantum chemical. PaDEL can be regarded as one of the better options
because it is free, open source, supports a majority of molecular file formats, and is fast.
The Mordred software package is based on PaDEL-Descriptor and it can calculate more
than 1800 2D and 3D descriptors. Mordred is open source and free just like PaDEL.
However, it is almost twice as fast as PaDEL [89]. The Mordred also can handle large
molecules which is often an issue for other packages. Overall, the PaDEL-Descriptor
software and the Mordred software can compute a plethora of varied but relevant
molecular descriptors from the structure of a compound.
Numeric Featurization
While humans can understand conceptual information, such as a compound being
acidic or basic, a computer relies on raw numbers and therefore, molecular concepts must
be converted to some numerical form [90]. This process, however, can be tricky when
avoiding non-informative or redundant features that may act as noise. There are several
ways to handle the procedure of feature selection: removing features that are highly
correlated with others, dropping features with low variance, or using regularization
techniques.
A conversion of categorical data into numerical values can arise another issue. A
simple approach to assign a number to each possible category could bias the computer
into seeing a non-existent order within the categories. For example, labeling acid as 0,
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base as 1, and neutral as 2 may cause the computer to interpret that an acid is less than a
base, which is less than a neutral compound. Of course, this ordered relationship does not
exist in reality. Instead, categorical features can be one-hot encoded to create a series of
bits that simply represent if a feature is present or not. A one-hot encoded feature is
treated as multiple numerical features, one bit for each possible case in the category. If a
particular case is present in the category, then that bit will become a 1, otherwise, it will
become a 0. So, for the acid-base category, two numeric features will be generated, one
bit (either 0 or 1) for an acid and another bit (either 0 or 1) for a base. If a compound is
neutral, then both the acid and base bits will be set to 0, indicating the third category.
Representing compounds using featurization can be difficult and may require
domain knowledge for the specific task. Fortunately, molecular fingerprints and the
molecular descriptor approaches to compound representation has been curated and tested
by many experts within the chemical and pharmaceutical fields and have been shown to
work well.
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Chapter 5
Cytochrome P450 3A4 Inhibitor Modeling
In silico methods for determining a compound’s potential to inhibit CYP3A4
could greatly reduce the time and resources spent on drug candidate development.
Inhibition prediction models can be built by selecting relevant features from compound
structures and correlating them to experimentally observed inhibition outcomes using the
data generated by in vitro assays. Machine learning techniques that analyze many data
samples can discover patterns in the feature space and make adequate predictions of the
inhibition potential for a new candidate molecule. The best model for separating already
known samples and generalizing the unknown data can be selected from the comparison
of various machine learning approaches and modeling techniques. The process of
creating a CYP3A4 inhibition model must consider many aspects, including the choice of
the dataset used for training, the procedure of molecular feature extraction from
compounds, the selection of the machine learning algorithm for model generation, etc.
Our workflow for building predictive models is presented in Figure 7.
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Figure 7. Methodological pipeline used to create predictive models.

Dataset Curation
A vital part of any successful prediction model is the data used to train it. The
quality of training data directly influences the accuracy of model predictions. PubChem
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AID: 1851 is a publicly available and frequently used dataset. It is often considered to be
the standard for CYP3A4 inhibition modeling [91]. Many compounds (n=17,143) were
studied in vitro using a luminescence-probe approach. CYP3A4, as well as many other
CYP enzymes, were used to catalyze the dealkylation of pro-luciferin substrates to
luciferin. Using luciferase detection reagent, luciferin could be measured with
luminescence. Various concentrations of the compounds were tested to determine the
compounds’ IC50 for the studied CYP enzymes from measured concentration−response
curves. In addition, the data on response curves contains curve classification that
specifies the completeness of the reaction and efficacy of the compound. PubChem
provides an activity score and an activity outcome, where the compounds are labeled as
active, if their activity score is 40 or more. Inactive compounds have a score of 0, and
inconclusive results if their activity score is less than 40 but greater than 0.
PubChem enables a publicly available RESTful API providing the access to data
tables corresponding to a user-selected assay. Substance IDs and specific table features,
like activity scores, can be retrieved over HTTPS protocol using the PubChem API.
CYP3A4 data were downloaded in a JSON1 format. A correspondent list of canonical
SMILES strings were obtained by matching activity data records using compound IDs.
All compounds, activity scores, and curve classifications in the AID: 1851 assay were
retrieved from PubChem, matched with SMILES structures, and filtered using an
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automated Python script. Please see Appendix A: pubchem.py and Appendix B for our
source code. The compounds were classified as follows:
•

inhibitors - compounds with an activity score ≥ 40 and a curve classification
of -1.1 (complete curve; high efficacy), -1.2(complete curve; partial efficacy),
or -2.1 (partial curve; high efficacy),

•

non-inhibitors - compounds with an activity score of 0 and a curve
classification of 4 (undefined),

•

inconclusive -- compounds that did not fall under either classification.
Compounds classified as inconclusive were excluded from the dataset.

PubChem fingerprints were generated by the PaDEL software for all included
compounds. The Mordred package was employed to generate molecular features. Our
final feature set included both PubChem fingerprints and Mordred generated molecular
features. In total, 10,832 compounds were selected for the training dataset. For each
compound in the dataset 1,826 molecular features were calculated and 881 fingerprint
bits were extracted. The source code for molecular descriptor generation is shown in
Appendix A: featurized.py.
Inhibitor Models
Four machine learning approaches were evaluated for the task of building a
prediction model for CYP3A4 inhibition: logistic regression, random forests, support
vector machine, and neural network. A logistic regression approach has the advantages of
being the fastest to train and use. Also, a logistic regression model is relatively easy to
modify and interpret. In comparison, random forests and support vector machine are
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more difficult to use and modify. However, these approaches often perform well on many
different tasks, and can be better generalized to new data. A neural network approach
offers the most potential in learning more complicated features in addition to the ones
already present. While the neural network approach can be much harder to interpret and
more complicated to use, it offers a significant increase in performance for many machine
learning tasks.
Model creation. All four machine learning models were implemented in Python
using the scikit-learn package [92], please see the details in Appendix C. The training
data went through several pre-processing steps:
1) missing data was imputed using the mean value of the relevant feature,
2) features were normalized to fall within a range of 0 to 1,
3) features with a variance less than a certain threshold were removed, and
4) classes were either balanced using a SMOTE or an under-sampling approach,
or classes were left unbalanced.
All pre-processing steps were conducted in a pipeline corresponding to a crossvalidated train-test split. The pre-processors were constructed using training dataset and
evaluated using the testing dataset.
The optimization of each model contained multiple hyperparameters. For
example, the logistic regression algorithm’s regularization factor can affect the weight of
each feature. For the random forests model, the number of estimators in the ensemble and
the fraction of features considered for each estimator can significantly alter the bias and
variance of the final model. For the support vector machine model, the regularization
50

parameter (lambda) and gamma can alter the weights of the features and the amount of
influence one sample has. Finally, for the neural network approach, the number of layers
and the number of nodes in each layer can greatly impact the bias and variance of the
model. Regularization can alter the weighting of each node, with high regularization
corresponding to a lower amount of strongly weighted nodes. All models went through
extensive tuning and optimization of the above model hyperparameters, as well as for
various pre-processing steps, using the open source hyperparameter optimization
framework Optuna [93].
Model performance and comparisons. To evaluate and compare the above
models, a 3-fold cross-validation approach was conducted on each of them. Prediction
accuracy was calculated and used to score each model. The best average cross-validation
accuracies for each model approach were the following:
•

logistic regression achieved an accuracy of 0.832,

•

random forests achieved an accuracy of 0.834,

•

support vector machine achieved an accuracy of 0.819, and

•

neural network achieved an accuracy of 0.823.

Overall, all models achieved a similar performance on accuracy that was
consistent with the results seen in literature. The cross-validated accuracies for each of
the 3-folds are compared in Figure 8. Random forests and logistic regression have similar
performances, though, random forests had a larger variance between the three cross
validated folds. Support vector machine had the worst performance of the four
approaches and a large variance between fold accuracies. The neural network approach
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had the most consistent accuracy measures between the three folds; however, these
accuracies were worse than those of both random forests and logistic regression. The
models performed best when the variance threshold was set lower, allowing for more
features to pass through to the model. The best class balancing technique for random
forests, support vector machine, and neural network was SMOTE, while logistic
regression preferred no balancing of classes. A more detailed overview of all
hyperparameters for each modeling approach is shown in Table 4.

Figure 8. Cross-validated (3-fold) accuracies for all standard modeling approaches.
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Table 4
Hyperparameter Optimization for Standard Models
Model

Hyperparameter

Range Considered

Best Value

Logistic Regression

Balance
Variance Threshold
C = 1 / regularization

{None, Under-sample, SMOTE}
[0, 0.25]
[1x10-5, 1x105]

None
0.00164
44772.5

Random Forests

Balance
Variance Threshold
Max Features
# Estimators

{None, Under-sample, SMOTE}
[0, 0.25]
[0.01, 1]
[1, 1000]

SMOTE
0.02322
0.36402
968

Support Vector
Machine

Balance
Variance Threshold
C = 1 / regularization
Gamma

{None, Under-sample, SMOTE}
[0, 0.25]
[1x10-5, 1x105]
[1x10-5, 1x105]

SMOTE
0.06889
691.286
0.06045

Neural Network

Balance
Variance Threshold
Alpha
Layers
Units in Layer 1
Units in Layer 2

{None, Under-sample, SMOTE}
[0, 0.25]
[1x10-10, 1x1010]
[1, 3]
[1, 300]
[1, 300]

SMOTE
0.01611
2.28473
2
140
181

Model Exploration
Exploring which features were most important to a model can bring insight into
the model’s predictive power and can showcase patterns between specific features and
labels. While some modeling approaches, such as logistic regression, can be easily
explained by viewing the weights of each feature, other approaches are harder to
comprehend by simply examining the weight values. The SHAP framework can be
employed to identify important features in a model, observe how fluctuations in feature
values effect the model output, and determine how features altered a model’s prediction
for a given sample. We implemented a series of model exploration tools, presented in
Appendix D.
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The top five features for each model are shown Figure 9. In all of the explored
models the two most important features were the atom-bond connectivity index (ABC)
[94] and the centered Moreau-Broto autocorrelation of lag 5 weighted by Allred-Rochow
electronegativity (ATSC5are) [95]. Additionally, all models had Graovac-Ghorbani
atom-bond connectivity index (ABCGG) [96] and centered Moreau-Broto autocorrelation
of lag 6 weighted by Allred-Rochow electronegativity (ATSC6are) within their top five
most important features. Logistic regression and random forests both shared the same top
5 features and also happen to be the best performing models. The support vector machine
model had 5-membered ring count (n5Ring) as a unique most important feature, while the
neural network model had shortest path diameter of adjacency matrix (SpDiam_A) as a
unique most important feature. We observed that higher ABC values indicate a higher
probability that the compound will be classified as an inhibitor in all of the explored
models.
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Figure 9. Most important features for standard modeling approaches.

Novel Machine Learning Approaches
We examined several modeling approaches for predicting CYP3A4 inhibitors.
However, all investigated models relied on external featurization of compounds, i.e. with
PaDEL, Mordered, or fingerprint techniques. While these techniques have been widely
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used in research, they all depend on tedious manual curation of the features. This may
lead to imprecise representations of the molecular structures and lack of relevance to the
prediction task at hand. Rather than rely on a human curated preprocessing step of
extracting molecular features from a SMILES string, the machine learning algorithm can
perform feature extraction instead. This removes the bias and dependence on a particular
molecular descriptor tool in feature generation, allowing for the model to learn relevant
features for a specific task without human intervention. The features extracted with this
machine learning approach are correspondent to detected patterns in the training data,
allowing the model to identify sub-structures within a compound that may be important
for the prediction task.
Neural network architectures can allow for auto-featurization though connecting
multiple nodes in different ways with tunable weights. Convolutional neural networks
can extend featurization from a 1-dimensional vector to a 2-dimensional matrix, 3dimensional matrix, or more [50]. A 1-dimensional convolutional layer can take a 2dimensional matrix and scan across one dimension with varying kernel sizes, while
filtering on the second dimension. This is often beneficial for finding temporal patterns in
one-hot encoded strings. A 2-dimensional convolutional layer performs similarly, except
it can scan across a 2-dimnesional matrix with an 𝑥 by 𝑦 kernel, while filtering on the
third dimension. Scanning in multiple dimensions is valuable for detecting spatial
patterns.
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To investigate these opportunities of auto-feature extraction, we developed two
novel approaches in CYP3A4 inhibition prediction based on work published by Hirohara
et al. [97]. Specifically, we focused on answering the following two question:
•

Can relevant molecular and structural features be extracted and used to
accurately predict the potential for CYP3A4 inhibition based on SMILES
strings?

•

Can relevant molecular and structural features be extracted and used to
accurately predict the potential for CYP3A4 inhibition based on a 2dimensional conformation of the compound’s atoms and bonds?

SMILES string auto-extraction. A molecule’s SMILES string holds information
about the structure of the compound, notating atoms that are bonded together, the bond
orders, rings, branching structures, and of course the symbol of the atoms present.
Treating a SMILES string as a temporal sequence of atoms and bonds can allow for
substructures to be identified and featurized from the SMILES string itself. To setup a
SMILES string into a numerical matrix that can be fed into a neural network, each
character in the string must be one-hot encoded, such that a specific character will receive
a specific bit in a vector, much like fingerprints. Through using one-hot encoding on all
characters in a SMILES string, a 2-dimensional numeric matrix is created. All the
dimension lengths of all SMILES matrices must be the same, thus, the matrices require
zero-padding. An example SMILES matrix can be seen in Table 5. In this example,
amifostine (NCCCNCCSP(=O)(O)O) was featurized using each character in the
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compound’s SMILES string. The columns represent each character in the SMILES string,
while the rows represent which feature the bit or integer refers too.

Table 5
SMILE Featurization Matrix for Amifostine
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Using 1D convolutional layers, the SMILES matrix can be scanned across the
first dimension representing SMILES characters, while pooling and filtering the second
dimension representing the one-hot encoded bit vectors. These convolutional layers can
be repeated, if beneficial, before inserting the extracted features into a dense layer of
nodes. A dense layer is not always needed. Although, one or more dense layers are often
added to the end of the model architecture. This architecture is visualized in Figure 10.

Figure 10. First two layers of the SMILE string auto-extraction architecture.

We achieved an accuracy of 0.823 after extensive tuning. The best model
consisted of two 1D convolutional layers with 27 and 13 filters, a kernel size of 5 and 4,
and a stride of 1 and 4. Dropout proportions of 0.35 and 0.47, respectively, were used to
reduce overfitting. Both convolutional layers used a rectified linear unit (ReLU)
activation function and were followed by batch normalization. The output layer consisted
of one densely connected node using a sigmoid activation function. Hyperparameter
details are available in Table 6. Overall, the SMILES string auto-extraction architecture
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provided similar accuracy to the standard models, while displaying ability for autofeaturization from SMILES strings.

Table 6
Hyperparameter Optimization for Auto-Extractor Models
Model

Hyperparameter

Range Considered

Best Value

SMILE Auto-Extraction

Conv Layers
Conv Layer 1 Filters
Conv Layer 1 Kernel
Conv Layer 1 Stride
Conv Layer 1 Dropout
Conv Layer 2 Filters
Conv Layer 2 Kernel
Conv Layer 2 Stride
Conv Layer 2 Dropout
Dense Layers

[1, 2]
[1, 50]
[1, 5]
[1, 5]
[0.2, 0.5]
[1, 50]
[1, 5]
[1, 5]
[0.2, 0.5]
[0, 1]

2
27
5
1
0.34915
13
4
4
0.46571
0

Structure Auto-Extraction

Conv Layers
Conv Layer 1 Filters
Conv Layer 1 Kernel
Conv Layer 1 Stride
Conv Layer 1 Dropout
Conv Layer 2 Filters
Conv Layer 2 Kernel
Conv Layer 2 Stride
Conv Layer 2 Dropout
Conv Layer 3 Filters
Conv Layer 3 Kernel
Conv Layer 3 Stride
Conv Layer 3 Dropout
Conv Layer 4 Filters
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Conv Layer 4 Dropout
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[1, 6]
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[1, 25]
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[0.2, 0.7]
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4
8
4
1
0.59298
3
25
1
0.69967
15
9
5
0.26906
4
17
3
0.43041
1
104
0.27760
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2D structure auto-extraction. Using the RDKit package, 2D conformations for
molecules can be computed from a SMILES string. The generated 2D conformations
provide structural information in the form of atom positioning measured in ångströms as
well as the bonds connecting atoms. Using the computed x, y coordinates for atoms, a 2D
matrix can be created to represent the coordinates at a specified resolution and scale. For
example, a 2D matrix consisting of 100x100 pixels can be created and the atom
coordinates can be converted into a -15 to 15 ångström scale, so that each atom
coordinate gets placed into a pixel within the matrix. The pixels to represent a bond can
be calculated using Bresenham's line algorithm, where the bond pixels are determined as
the best pixelated line from one atom pixel to the other. Atom’s in the matrix can be
encoded by their atomic mass, while bonds can be encoded by their bond order. To avoid
potential overlapping coordinates of atoms and bonds, two different filters can be
constructed for a given 2D matrix, one for atoms and one for bonds. Effectively, each
SMILES will result in a [100x100x2] matrix representing the atomic structure. A
flattened example of these pixel matrices for Chlorzoxazone and Voriconazole can be
seen in Figure 11.
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Figure 11. 100x100 pixel matrix displaying Chlorzoxazone and Voriconazole.

Using 2D convolutional layers, the structural matrix can be scanned across the x,
y dimensions with a rectangular kernel, while pooling and filtering the third dimension of
atom and bond filters. These convolutional layers can be repeated if beneficial, before
inserting the extracted features into a dense layer of nodes.
The highest accuracy achieved for the best model based on the 2D structure
extractor was 0.764, which falls short of the other models, but still shows the promising
potential for this approach. The best model for the 2D structure extractor approach
consisted of four 2D convolutional layers with 8, 3, 15 and 4 filters, a kernel size of 4, 25,
9, and 17, and a stride of 1, 1, 5, and 3. Following the convolutional layers, 1 dense layer
was added with 104 units. Dropout was used on all layers with dropout proportions of
0.59, 0.70, 0.27, and 0.43 for the convolutional layers, respectively, and a dropout
proportion of 0.28 for the dense layer. All layers used a rectified linear unit (ReLU)
activation function and were followed by batch normalization. The output layer consisted

62

of one densely connected node using a sigmoid activation function. Hyperparameter
details are summarized in Table 6.
Overall, the 2D structure auto-extraction architecture had a lower accuracy than
other models. However, it performed reasonably well to be considered for further
optimization. The performances of both auto-extractor models are compared in Figure 12.
Random forests, the best performing model, was significantly better than the 2D structure
auto-extraction approach. Although it was only marginally better than the SMILES string
auto-extraction technique. Both novel approaches achieved accuracies greater than 75%.

Figure 12. Cross-validated (3-fold) accuracies for auto-extraction approaches.
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Validation on Known CYP3A4 Inhibitors
A set of compounds published by the FDA as either strong, moderate, or weak
clinical inhibitors was passed into each model to determine its predictive performance.
Inhibition probabilities were calculated for all compounds in each of the tested models.
The summary of results for all the models is shown in Figure 13. Logistic regression
performed the best with 24 out of 33 samples classified correctly as inhibitors, followed
by both convolutional auto-extractor models correctly predicting 16. The Random forests
model correctly predicted 13 inhibitors, the neural network model predicted 12, and the
support vector machine model predicted only 7. We did not detect a trend in prediction
confidence from strong to weak inhibitors for any model. This was anticipated because
the strength of inhibition was not considered when we trained the models. Please note,
that these predictions are not an indication of model accuracy as only inhibitors were
included in this test set. Instead, these results are an indication of the models’ recall on
inhibitors, or the models’ ability to correctly classify a true inhibitor.
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Figure 13. Inhibition prediction probabilities on FDA inhibitors for all models.

For each model, we created a SHAP force plot showing the best and the worst
predictions as well as providing an insight as to which variables were most influential.
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Figure 14 illustrates the generated SHAP force plots. For logistic regression, cobicistat2
was correctly predicted as an inhibitor with the most confidence. The two features that
were deemed most important to this decision were centered Moreau-Broto
autocorrelation of lag 8 weighted by Van der Waals volume (ATSC8v) and MoreauBroto autocorrelation of lag 8 weighted by sigma electrons (ATS8d) [95]. The inhibition
prediction with the lowest confidence was for the compound chlorzoxazone3. The Geary
coefficient of lag 4 weighted by ionization potential (GATS4i) [98] weighted the
classification towards an inhibitor. However, the average Moreau-Broto autocorrelation
of lag 0 weighted by Pauling electronegativity (AATS0pe), and the presence of PubChem
fingerprint 669 (Cl-C:C-C=O) [86] confused the model and caused an incorrect
prediction of non-inhibitor.

2
3

Drug molecule for use in the treatment of human immunodeficiency virus infection (HIV/AIDS)
Drug molecule for use as muscle relaxant to treat muscle spasm and the resulting pain or discomfort.

66

Figure 14. SHAP force plots for the best and worst FDA test predictions.

Specific to the 2D structure auto-extractor approach, we can explore the spatial
areas and potentially the sub-structures within a compound that are most influential to the
model using SHAP values. An example of this exploration is shown in Figure 15 with
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chlorzoxazone and voriconazole4. Pixels that are shaded red contribute more towards a
classification of inhibitor, while pixels shaded blue contribute more towards the noninhibitor classification. The 2D structure model incorrectly classificed voriconazole as a
non-inhibitor, likely because of the 3 ring structures present around the center of the
molecule as indicated by the blue shading.

Figure 15. 2D SHAP values for predictions on Chlorzoxazone and Voriconazole.

4

Drug molecule known as antifungal medication, used to treat a number of fungal infections.
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Chapter 6
Conclusions and Future Opportunities
Four machine learning methods, logistic regression, random forests, support
vector machine, and artificial neural network were used to create classification models to
link compound structures with their ability to inhibit CYP3A4 activity. All models shared
the same training set derived from the PubChem AID: 1851 dataset. Two new approaches
for extracting molecular features from compound structures were developed and
investigated: 1) external featurization using Mordred, and 2) feature auto-extraction from
the SMILES representation of the compounds’ structure using CNNs. The results of the
featurization approaches showed that the random forests models based on external
featurization performed significantly better than the 2D structure auto-extraction
approach. However, its performance was only marginally better than the SMILES string
auto-extraction technique which requires farther study and optimization.
Two features: 1) the atom-bond connectivity index (ABC) and 2) the centered
Moreau-Broto autocorrelation of lag 5 weighted by Allred-Rochow electronegativity
(ATSC5are) were assigned the highest importance in all models based on external
featurization. Additionally, all models based on external featurization share GraovacGhorbani atom-bond connectivity index (ABCGG) and centered Moreau-Broto
autocorrelation of lag 6 weighted by Allred-Rochow electronegativity (ATSC6are) as
part of their top five features.
All studied models performed well (greater than 75% accuracy) at classifying
compounds as either inhibitors or non-inhibitors. Random forests and logistic regression
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performed the best with accuracies of 0.834 and 0.832, respectively. Although, Random
forests had a larger variance between the three cross validated folds. Support vector
machine had the worst performance of the four approaches and a large variance between
fold accuracies. The neural network approach had the most consistent accuracy measures
between the three folds.
All developed models were validated on the set of compounds published by the
FDA. Logistic regression performed the best with 24 out of 33 compounds correctly
classified as inhibitors, followed by both convolutional auto-extractor models correctly
predicting 16, the random forests model predicting 13, the neural network model
predicting 12, and the support vector machine model predicting only 7.
The modeling methods implemented in this study are not limited to predicting
only CYP3A4 inhibitors. Rather, they can learn to predict any activity for a given target.
Possible model expansion can be achieved through adding more refined data labels and
changing classification output from a binary case to a spectrum consisting of multiple
labels, e.g. strong, medium, or weak inhibitors labels. These added classes could improve
predictive power as compound activity may not be binary. Studied models can be
expanded into predicting compound’s activity on a continuous scale yielding a numerical
measure of compound’s potency towards a target. In addition to possible model
improvements from refined labels, the number of compounds in the training dataset
should be increased as well. It is important to ensure that new data is readily available for
improved models as new compounds are tested in vitro and/or in vivo. Models could
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continuously learn and improve their predictive power over time by connecting to a
downstream data pipeline.
Research into model exploration tools could find important substructures within a
compound. If the substructure is important for the binding task, it should be present more
often in samples with high binding activities. Models such as the SMILES string autoextractor or the 2D structure auto-extractor can assign high weights to nodes relating to
these substructures. This allows for diagnostic tools to explore models and discover
highly weighted substructures within the compounds.
Predicting a compound’s potential to inhibit an enzyme such as CYP3A4 is
important. However, adjusting the compound to remove inhibitory activity is another
complicated but crucial step. A tool that generates potential compound derivates from a
parent compound could be incorporated in predictive models. After generating all
derivatives, each compound could have, for example, their CYP3A4 inhibition potential
predicted. From these predictions, the tool can score each derivative and display them to
a chemist for further considerations. A tool like this could assist with structural
modification on drug candidates, allowing for chemists to find paths that remove or
greatly diminish the inhibitory affects.
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Appendix A
Scripts
featurized.py
import os
import re
import numpy as np
import pandas as pd
from mordred import Calculator, descriptors
from padelpy import padeldescriptor
from rdkit import Chem
from rdkit.Chem import AllChem
from sklearn.preprocessing import OneHotEncoder
from tqdm import notebook
def generate_descriptors(smiles):
"""
Generate molecular descriptors using the Mordred package for a list of SMILE strings.
:param smiles: An iterable collection of SMILE strings.
:return: A pandas data frame of generated mordred descriptors by SMILE string.
"""
descriptors_table = np.ndarray((len(smiles), 1826), dtype=object)
print("Generating mordred descriptors:")
for index in notebook.tqdm(range(descriptors_table.shape[0])):
structure = smiles[index]
mol = Chem.MolFromSmiles(structure)
if mol is None:
descriptors_table[index, :] = [None] * 1826
else:
AllChem.EmbedMolecule(mol, useExpTorsionAnglePrefs=True, useBasicKnowledge=True)
descriptors_table[index, :] = Calculator(descriptors, ignore_3D=False)(mol).fill_missing()
return pd.DataFrame(descriptors_table, columns=Calculator(descriptors, ignore_3D=False).descriptors)
def generate_fingerprints(smiles: pd.Series) -> pd.DataFrame:
"""
Generate PubChem fingerprints for a list of SMILE strings using PaDEL.
:param smiles: A pandas series of SMILE strings.
:return: A pandas data frame of PubChem fingerprint bits by SMILE string.
"""
print("Generating fingerprints:")
smiles.to_csv("temp_smiles.smi", index=False, header=False)
padeldescriptor(mol_dir="temp_smiles.smi",d_file="fingerprints.csv",fingerprints=True,retainorder=True)
fingerprints_table = pd.read_csv("fingerprints.csv").drop("Name", axis="columns")
os.remove("temp_smiles.smi")
os.remove("fingerprints.csv")
print("\tDone.\n")
return fingerprints_table
def extract_smiles(smiles, max_length=250) -> np.ndarray:
"""
Extract a stack of one-hot encoded 2D matrices from a list of SMILE strings.
:param smiles: An iterable collection of SMILE strings.
:param max_length: The length of the SMILE string dimension, those shorter than this are 0-padded to this length.
:return: A 3-dimensional ndarray of (samples, smile positions, one-hot encoded features).
"""
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smile_list = []
print("Extracting SMILE matrices:")
for smile in notebook.tqdm(smiles):
smile_list.append(__extract_smile_features(smile, max_length))
return np.stack(smile_list)
def extract_smile_structures(smiles, resolution=100, scale=(-15, 15)) -> np.ndarray:
"""
Extract a stack of 2-dimensional matricies from a list of SMILE strings.
:param smiles: An iterable collection of SMILE strings.
:return: A 4-dimensional ndarray of (samples, x-coordinates, y-coordinates, filters).
"""
mol_list = []
print("Extracting 2D structures:")
for smile in notebook.tqdm(smiles):
matrix = None
mol = Chem.MolFromSmiles(smile)
if mol is not None:
mol.Compute2DCoords()
matrix = __extract_mol_structure(mol, 0, resolution, scale)
if matrix is None:
matrix = np.full((resolution, resolution, 2), -1, dtype='b')
mol_list.append(matrix)
return np.stack(mol_list)
def __extract_atom_features(molecule, atom_index):
symbol_features = []
atom = molecule.GetAtomWithIdx(atom_index)
symbol_features.append(atom.GetSymbol())
symbol_features.append(atom.GetTotalNumHs())
symbol_features.append(atom.GetTotalDegree())
symbol_features.append(atom.GetFormalCharge())
symbol_features.append(atom.GetTotalValence())
symbol_features.append(atom.IsInRing() * 1)
symbol_features.append(atom.GetIsAromatic() * 1)
symbol_features.append(str(atom.GetChiralTag()))
symbol_features.append(str(atom.GetHybridization()))
symbol_features.append(0)
two_char_abbr_flag = True if len(atom.GetSymbol()) > 1 else False
return symbol_features, two_char_abbr_flag
def __extract_smile_features(smile, max_length):
molecule = Chem.MolFromSmiles(smile)
ion_flag = False
two_char_abbr_flag = False
two_digit_ring_flag = False
ring_first_digit = 0
ring_indices = []
atom_index = 0
smile_array = []
if molecule:
for character in smile:
if re.match(r'[a-gi-z]', character, re.IGNORECASE):
if two_char_abbr_flag:
two_char_abbr_flag = False
else:
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symbol_features, two_char_abbr_flag = __extract_atom_features(molecule, atom_index)
smile_array.append(symbol_features)
atom_index += 1
elif re.match(r'[\\/.=#)(]', character):
symbol_features = [character, 0, 0, 0, 0, 0, 0, 'CHI_UNSPECIFIED', 'UNSPECIFIED', 0]
smile_array.append(symbol_features)
elif re.match(r'[+-]', character):
ion_flag = True
elif re.match(r']', character):
ion_flag = False
elif re.match(r'%', character):
two_digit_ring_flag = True
elif re.match(r'[0-9]', character):
if two_digit_ring_flag:
if ring_first_digit == 0:
ring_first_digit = character
continue
else:
character = ring_first_digit + character
ring_first_digit = 0
two_digit_ring_flag = False
if not ion_flag:
symbol_features = ['ring']
if character not in ring_indices:
# Ring start.
symbol_features.extend([0, 0, 0, 0, 0, 0, 'CHI_UNSPECIFIED', 'UNSPECIFIED', 1])
ring_indices.append(character)
else:
# Ring end.
symbol_features.extend([0, 0, 0, 0, 0, 0, 'CHI_UNSPECIFIED', 'UNSPECIFIED', 2])
smile_array.append(symbol_features)
# 0-Padding
smile_array.extend([[0] * 10] * (max_length - len(smile_array)))
smile_array = pd.DataFrame(smile_array)
encoder = OneHotEncoder([['C', 'N', 'O', 'Br', 'Cl', 'F', 'P', 'S', 'ring', '(', ')', '/', '\\', '=', '#'],
['CHI_TETRAHEDRAL_CCW', 'CHI_TETRAHEDRAL_CW'],
['SP', 'SP2', 'SP3'], ['1', '2']], sparse=False, handle_unknown='ignore')
smile_array = np.concatenate([smile_array[[1, 2, 3, 4, 5, 6]].to_numpy(),
encoder.fit_transform(smile_array[[0, 7, 8, 9]].astype(str))], axis=1)
return smile_array
def __extract_mol_structure(mol, conf_id, resolution, scale):
digitizer = {'SINGLE': 1, 'AROMATIC': 2, 'DOUBLE': 3, 'TRIPLE': 4, 'C': 6, 'N': 7, 'O': 8, 'F': 9, 'P': 15, 'S': 16,
'Cl': 17, 'Br': 35, 'Other': 40}
pixel_scale = (scale[1] - scale[0]) / resolution
matrix = np.zeros((resolution, resolution, 2), dtype='b')
conformer = mol.GetConformer(conf_id)
for atom in mol.GetAtoms():
symbol = atom.GetSymbol()
x = conformer.GetAtomPosition(atom.GetIdx()).x
y = conformer.GetAtomPosition(atom.GetIdx()).y
if x < scale[0] or x > scale[1] or y < scale[0] or y > scale[1]:
return None
j = int(np.floor((x - scale[0]) / pixel_scale))
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i = int(np.floor((scale[1] - y) / pixel_scale))
if symbol not in digitizer.keys():
symbol = 'Other'
matrix[i, j, 0] = digitizer[symbol]
for bond in mol.GetBonds():
bond_type = bond.GetBondType()
x_start = conformer.GetAtomPosition(bond.GetBeginAtomIdx()).x
y_start = conformer.GetAtomPosition(bond.GetBeginAtomIdx()).y
j_start = int(np.floor((x_start - scale[0]) / pixel_scale))
i_start = int(np.floor((scale[1] - y_start) / pixel_scale))
x_end = conformer.GetAtomPosition(bond.GetEndAtomIdx()).x
y_end = conformer.GetAtomPosition(bond.GetEndAtomIdx()).y
j_end = int(np.floor((x_end - scale[0]) / pixel_scale))
i_end = int(np.floor((scale[1] - y_end) / pixel_scale))
pixel_coords = __pixelate(i_start, j_start, i_end, j_end)
for pixel in pixel_coords[1:]:
matrix[pixel[0], pixel[1], 1] = digitizer[str(bond_type)]
return matrix
def __pixelate(x0, y0, x1, y1):
pixel_coords = []
if abs(y1 - y0) < abs(x1 - x0):
if x0 > x1:
x0, x1 = x1, x0
y0, y1 = y1, y0
dx = x1 - x0
dy = y1 - y0
yi = 1
if dy < 0:
yi = -1
dy = -dy
d = 2 * dy - dx
y = y0
for x in range(x0, x1):
pixel_coords.append((x, y))
if d > 0:
y += yi
d -= 2 * dx
d += 2 * dy
else:
if y0 > y1:
x0, x1 = x1, x0
y0, y1 = y1, y0
dx = x1 - x0
dy = y1 - y0
xi = 1
if dx < 0:
xi = -1
dx = -dx
d = 2 * dx - dy
x = x0
for y in range(y0, y1):
pixel_coords.append((x, y))
if d > 0:
x += xi
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d -= 2 * dy
d += 2 * dx
return pixel_coords

export.py
from joblib import dump
from tensorflow.keras.wrappers.scikit_learn import KerasClassifier
def export_model(score, classifier, x, y, filepath, study):
try:
if score > study.best_value:
__export_models(classifier, x, y, filepath)
except ValueError:
__export_models(classifier, x, y, filepath)
def __export_models(classifier, x, y, filepath):
classifier.fit(x, y)
if type(classifier) == KerasClassifier:
classifier.model.save(filepath)
else:
dump(classifier, filepath)

pubchem.py
import numpy as np
import requests
def get_assay_results(aid, tids=None):
assay_results = []
url = f'https://pubchem.ncbi.nlm.nih.gov/rest/pug/assay/aid/{aid}'
request = requests.get(f'{url}/sids/json')
sids = request.json()['InformationList']['Information'][0]['SID']
limit = 10000
batches = [sids[i * limit:(i + 1) * limit] for i in range((len(sids) + limit - 1) // limit)]
for batch in batches:
request = requests.post(f'{url}/json', data={'sid': ','.join(map(str, batch))})
data = request.json()['PC_AssaySubmit']['data']
for compound in data:
if tids is None:
props = [list(prop['value'].values())[0] for prop in compound['data']]
else:
props = [list(prop['value'].values())[0] for prop in compound['data'] if prop['tid'] in tids]
assay_results.append([compound['sid']] + props)
return np.array(assay_results, dtype=object)
def get_smile(sids):
url = f'https://pubchem.ncbi.nlm.nih.gov/rest/pug/assay/substance/sid/cids/json'
request = requests.post(url, data={'sid': ','.join(map(str, sids))})
compounds = request.json()['InformationList']['Information']
smile_table = np.ndarray((len(compounds), 2), dtype=object)
for index in range(smile_table.shape[0]):
smile_table[index, 0] = compounds[index]['CID'][0] if 'CID' in compounds[index] else None
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cids = smile_table[smile_table[:, 0] != None, 0].astype(int)
url = f'https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/property/CanonicalSMILES/json'
request = requests.post(url, data={'cid': ','.join(map(str, cids))})
smiles = request.json()['PropertyTable']['Properties']
smiles_index = 0
for index in range(smile_table.shape[0]):
smile = smiles[smiles_index]
if smile_table[index, 0] == smile['CID']:
smile_table[index, 1] = smile['CanonicalSMILES']
smiles_index += 1
else:
smile_table[index, 1] = None
return smile_table
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Appendix B
Data Retrieval
import numpy as np
import pandas as pd
from featurize import generate_descriptors, generate_fingerprints, extract_smiles, extract_smile_structures
from pubchem import get_assay_results, get_smile
def create_labeled_dataset():
assay_data = get_assay_results(aid='1851', tids={60, 68})
assay_data = pd.DataFrame(assay_data, columns=['sid', 'score', 'curve_class'], dtype='object')
smiles = get_smile(sids=assay_data.iloc[:, 0].astype(int))
smiles = pd.DataFrame(smiles, columns=['cid', 'smile'])
assay_data = pd.concat((smiles.smile, assay_data.iloc[:, [1, 2]]), axis=1).dropna()
inhibitor = assay_data.loc[(assay_data.score >= 40) & assay_data.curve_class.isin({-1.1, -1.2, -2.1}), ['smile']]
inhibitor['label'] = 'inhibitor'
noninhibitor = assay_data.loc[(assay_data.score == 0) & (assay_data.curve_class == 4), ['smile']]
noninhibitor['label'] = 'noninhibitor'
return pd.concat((inhibitor, noninhibitor), axis=0).drop_duplicates('smile').reset_index(drop=True)
labeled_data = create_labeled_dataset()
mordred_features = generate_descriptors(labeled_data.smile.to_list())
fingerprints = generate_fingerprints(labeled_data.smile)
labeled_data = pd.concat([labeled_data, mordred_features, fingerprints], axis=1)
labeled_data.to_csv('data/cyp3a4_labeled_data.csv', index=False)
smile_features = extract_smiles(labeled_data.smile, max_length=250)
np.save('data/cyp3a4_smile_features', smile_features)
smile_structure = extract_smile_structures(labeled_data.smile, resolution=100, scale=(-15, 15))
np.save('data/cyp3a4_smile_structure', smile_structure)
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Appendix C
Models
import numpy as np
import pandas as pd
import optuna
import matplotlib.pyplot as plt
from imblearn import over_sampling, under_sampling, pipeline
from sklearn import ensemble, svm, linear_model, neural_network
from sklearn import impute, feature_selection, preprocessing, model_selection
from tensorflow.keras import Sequential, Input
from tensorflow.keras.layers import Conv1D, Conv2D, Dense, Dropout, Flatten, BatchNormalization
from tensorflow.keras.optimizers import Adam
from tensorflow.keras.wrappers.scikit_learn import KerasClassifier
from export import export_model
df = pd.read_csv('data/cyp3a4_labeled_data.csv', low_memory=False)
features = df.drop(['smile', 'label'], axis=1)
smile_features = np.load('data/cyp3a4_smile_features.npy', allow_pickle=True)
smile_structure = np.load('data/cyp3a4_smile_structure.npy', allow_pickle=True)
labels = df.label.values.reshape(-1)
db_path = 'sqlite:///data/p450_ml.db'
best_scores = {'Logistic Regression': [], 'Random Forest': [], 'Support Vector Machine': [],
'Neural Network': [], 'SMILE Auto-Extractor': [], 'Structure Auto-Extractor': []}
def create_pipe(trial):
pipe = []
pipe.append(impute.SimpleImputer())
pipe.append(preprocessing.MinMaxScaler())
pipe.append(feature_selection.VarianceThreshold(trial.suggest_uniform('var_thresh', 0, 0.25)))
balance = trial.suggest_int('balance', 0, 2)
if balance == 2:
pipe.append(over_sampling.SMOTE())
elif balance == 1:
pipe.append(under_sampling.RandomUnderSampler())
return pipe
def log_score(scores, name):
try:
if scores.mean() > study.best_value:
best_scores[name] = scores
except ValueError:
best_scores[name] = scores
def objective(trial):
pipe = create_pipe(trial)
pipe.append(linear_model.LogisticRegression(C=trial.suggest_loguniform('c', 1e-5, 1e5)))
classifier = pipeline.make_pipeline(*pipe)
scores = model_selection.cross_val_score(classifier, features, labels, scoring='accuracy',
cv=model_selection.StratifiedKFold(3, shuffle=True), n_jobs=3)
log_score(scores, 'Logistic Regression')
export_model(scores.mean(), classifier, features, labels, 'models/lr-model.joblib', study)
return scores.mean()
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study = optuna.create_study(study_name='lr', storage=db_path, direction='maximize', load_if_exists=True)
study.optimize(objective, n_trials=50)
fig = optuna.visualization.plot_optimization_history(study)
fig.show()
fig = optuna.visualization.plot_slice(study)
fig.show()
def objective(trial):
pipe = create_pipe(trial)
pipe.append(ensemble.RandomForestClassifier(max_features=trial.suggest_loguniform('max_features', 0.01,
1), n_estimators=trial.suggest_int('n_estimators', 1, 1000)))
classifier = make_pipeline(*pipe)
scores = model_selection.cross_val_score(classifier, features, labels, scoring='accuracy',
cv=model_selection.StratifiedKFold(3, shuffle=True), n_jobs=3)
log_score(scores, 'Random Forest')
export_model(scores.mean(), classifier, features, labels, 'models/rf-model.joblib', study)
return scores.mean()
study = optuna.create_study(study_name='rf', storage=db_path, direction='maximize', load_if_exists=True)
study.optimize(objective, n_trials=50)
fig = optuna.visualization.plot_optimization_history(study)
fig.show()
fig = optuna.visualization.plot_slice(study)
fig.show()
def objective(trial):
pipe = create_pipe(trial)
pipe.append(svm.SVC(C=trial.suggest_loguniform('c', 1e-5, 1e5), gamma=trial.suggest_loguniform('gamma',
1e-5, 1e5), probability=True))
classifier = make_pipeline(*pipe)
scores = model_selection.cross_val_score(classifier, features, labels, scoring='accuracy',
cv=model_selection.StratifiedKFold(3, shuffle=True), n_jobs=3)
log_score(scores, 'Support Vector Machine')
export_model(scores.mean(), classifier, features, labels, 'models/svm-model.joblib', study)
return scores.mean()
study = optuna.create_study(study_name='svm', storage=db_path, direction='maximize', load_if_exists=True)
study.optimize(objective, n_trials=15)
fig = optuna.visualization.plot_optimization_history(study)
fig.show()
fig = optuna.visualization.plot_slice(study)
fig.show()
def objective(trial):
pipe = create_pipe(trial)
layers = []
for i in range(trial.suggest_int('layers', 1, 3)):
n_units = trial.suggest_int(f'units_{i}', 1, 300)
layers.append(n_units)
pipe.append(neural_network.MLPClassifier(hidden_layer_sizes=tuple(layers),
alpha=trial.suggest_loguniform('alpha', 1e-10, 1e10)))
classifier = make_pipeline(*pipe)
scores = model_selection.cross_val_score(classifier, features, labels, scoring='accuracy',
cv=model_selection.StratifiedKFold(3, shuffle=True), n_jobs=3)
log_score(scores, 'Neural Network')
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export_model(scores.mean(), classifier, features, labels, 'models/nn-model.joblib', study)
return scores.mean()
study = optuna.create_study(study_name='nn', storage=db_path, direction='maximize', load_if_exists=True)
study.optimize(objective, n_trials=50)
fig = optuna.visualization.plot_optimization_history(study)
fig.show()
fig = optuna.visualization.plot_slice(study)
fig.show()
def build_cnn_model_1d(cnn_layers=(64, 3, 1, 0.4), dense_layers=(32, 0.4), learning_rate=0.001,
shape=(250, 28)):
model = Sequential()
model.add(Input(shape=shape))
for layer in cnn_layers:
model.add(Conv1D(filters=layer[0], kernel_size=layer[1], strides=layer[2], activation='relu'))
model.add(BatchNormalization(axis=2))
if layer[3] > 0:
model.add(Dropout(layer[3]))
model.add(Flatten())
for layer in dense_layers:
model.add(Dense(units=layer[0], activation='relu'))
model.add(BatchNormalization(axis=1))
if layer[1] > 0:
model.add(Dropout(layer[1]))
model.add(Dense(units=1, activation='sigmoid'))
model.compile(optimizer=Adam(lr=learning_rate), loss="binary_crossentropy", metrics=["accuracy"])
return model
def objective(trial):
cnn_layers = []
for i in range(trial.suggest_int('cnn_layers', 1, 2)):
filters = trial.suggest_int(f'filter_{i}', 1, 50)
kernel = trial.suggest_int(f'kernel_{i}', 1, 5)
stride = trial.suggest_int(f'stride_{i}', 1, 5)
dropout = trial.suggest_uniform(f'dropout_cnn_{i}', 0.2, 0.5)
cnn_layers.append((filters, kernel, stride, dropout))
dense_layers = []
for i in range(trial.suggest_int('dense_layers', 0, 1)):
n_units = trial.suggest_int(f'unit_{i}', 1, 50)
dropout = trial.suggest_uniform(f'dropout_nn_{i}', 0.2, 0.5)
dense_layers.append((n_units, dropout))
classifier = KerasClassifier(build_fn=build_cnn_model_1d, epochs=100, batch_size=32, learning_rate=0.0005,
verbose=0, cnn_layers=tuple(cnn_layers), dense_layers=tuple(dense_layers))
scores = model_selection.cross_val_score(classifier, smile_features, labels, scoring='accuracy',
cv=model_selection.StratifiedKFold(3, shuffle=True))
log_score(scores, 'SMILE Auto-Extractor')
export_model(scores.mean(), classifier, smile_features, labels, 'models/cnn-model.h5', study)
return scores.mean()
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study = optuna.create_study(study_name='cnn', storage=db_path, direction='maximize', load_if_exists=True)
study.optimize(objective, n_trials=50)
fig = optuna.visualization.plot_optimization_history(study)
fig.show()
fig = optuna.visualization.plot_slice(study)
fig.show()
def build_cnn_model_2d(cnn_layers=(64, 3, 1, 0.4), dense_layers=(32, 0.4), learning_rate=0.001,
shape=(100, 100, 2)):
model = Sequential()
model.add(Input(shape=shape))
for layer in cnn_layers:
model.add(Conv2D(filters=layer[0], kernel_size=layer[1], strides=layer[2], padding="same",
activation='relu'))
model.add(BatchNormalization(axis=2))
if layer[3] > 0:
model.add(Dropout(layer[3]))
model.add(Flatten())
for layer in dense_layers:
model.add(Dense(units=layer[0], activation='relu'))
model.add(BatchNormalization(axis=1))
if layer[1] > 0:
model.add(Dropout(layer[1]))
model.add(Dense(units=1, activation='sigmoid'))
model.compile(optimizer=Adam(lr=learning_rate), loss="binary_crossentropy", metrics=["accuracy"])
return model
def objective(trial):
cnn_layers = []
for i in range(trial.suggest_int('cnn_layers', 1, 6)):
filters = trial.suggest_int(f'filter_{i}', 1, 20)
kernel = trial.suggest_int(f'kernel_{i}', 1, 25)
stride = trial.suggest_int(f'stride_{i}', 1, 5)
dropout = trial.suggest_uniform(f'dropout_cnn_{i}', 0.2, 0.7)
cnn_layers.append((filters, kernel, stride, dropout))
dense_layers = []
for i in range(trial.suggest_int('dense_layers', 0, 1)):
n_units = trial.suggest_int(f'unit_{i}', 75, 250)
dropout = trial.suggest_uniform(f'dropout_nn_{i}', 0, 0.5)
dense_layers.append((n_units, dropout))
classifier = KerasClassifier(build_fn=build_cnn_model_2d, epochs=75, batch_size=64, learning_rate=0.001,
verbose=0, cnn_layers=tuple(cnn_layers), dense_layers=tuple(dense_layers))
scores = model_selection.cross_val_score(classifier, smile_structure, labels, scoring='accuracy',
cv=model_selection.StratifiedKFold(3, shuffle=True))
log_score(scores, 'Structure Auto-Extractor')
export_model(scores.mean(), classifier, smile_structure, labels, 'models/2d-cnn-model.h5', study)
return scores.mean()
study = optuna.create_study(study_name='2d-cnn', storage=db_path, direction='maximize',load_if_exists=True)
study.optimize(objective, n_trials=50)
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fig = optuna.visualization.plot_optimization_history(study)
fig.show()
fig = optuna.visualization.plot_slice(study)
fig.show()
scores = list(best_scores.values())[:4]
labels = list(best_scores.keys())[:4]
plt.figure(figsize=(6, 3), dpi=300)
plt.rcParams.update({'font.size': 7})
plt.xticks(rotation=0)
plt.ylim(0.74, 0.86)
plt.ylabel('3-Fold Cross-Validation Accuracy')
plt.boxplot(scores, labels=labels, boxprops={"linewidth": 0.8},
medianprops={"color": 'black', "linewidth": 0.8},
whiskerprops={"linewidth": 0.8}, capprops={"linewidth": 0.8})
for i in range(len(scores)):
y = scores[i]
x = np.random.normal(i+0.7, 0, size=len(y))
plt.plot(x, y, 'k.', markersize=2)
plt.savefig('images/cv_accuracies_standard.svg')
scores = list(best_scores.values())
scores = [scores[i] for i in [1, 4, 5]]
labels = list(best_scores.keys())
labels = [labels[i] for i in [1, 4, 5]]
plt.figure(figsize=(6, 3), dpi=300)
plt.rcParams.update({'font.size': 7})
plt.xticks(rotation=0)
plt.ylim(0.74, 0.86)
plt.ylabel('3-Fold Cross-Validation Accuracy')
plt.boxplot(scores, labels=labels, boxprops={"linewidth": 0.8},
medianprops={"color": 'black', "linewidth": 0.8},
whiskerprops={"linewidth": 0.8}, capprops={"linewidth": 0.8})
for i in range(len(scores)):
y = scores[i]
x = np.random.normal(i+0.7, 0, size=len(y))
plt.plot(x, y, 'k.', markersize=2)
plt.savefig('images/cv_accuracies_auto_extract.svg')
study = optuna.load_study(study_name='lr', storage=db_path)
study.best_params
study = optuna.load_study(study_name='rf', storage=db_path)
study.best_params
study = optuna.load_study(study_name='svm', storage=db_path)
study.best_params
study = optuna.load_study(study_name='nn', storage=db_path)
study.best_params
study = optuna.load_study(study_name='cnn', storage=db_path)
study.best_params
study = optuna.load_study(study_name='2d-cnn', storage=db_path)
study.best_params
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Appendix D
Exploration
import pandas as pd
import matplotlib.pyplot as plt
from joblib import load
import shap
import os
import warnings
warnings.filterwarnings('ignore')
df = pd.read_csv('data/cyp3a4_labeled_data.csv', low_memory=False)
features = df.drop(['smile', 'label'], axis=1).astype(float)
def adjust_plot(title, colorbar_label):
plt.title(title, fontsize=11)
ax = plt.gcf().axes[0]
for label in (ax.get_xticklabels() + ax.get_yticklabels()):
label.set_fontsize(8)
for label in [ax.xaxis.label, ax.yaxis.label]:
label.set_fontsize(10)
ax = plt.gcf().axes[1]
for label in (ax.get_yticklabels()):
label.set_fontsize(8)
if colorbar_label:
ax.yaxis.label.set_fontsize(10)
else:
ax.set_ylabel('')
plt.tight_layout()
def shap_feature_importance(features, model, title, save_path, sample_size=100):
samples = shap.sample(features, sample_size)
explainer = shap.KernelExplainer(model.predict_proba, samples)
shap_values = explainer.shap_values(samples, nsamples=5, l1_reg="aic")
shap.summary_plot(shap_values[0], samples, feature_names=samples.columns, max_display=5,
plot_size=(6, 2), show=False)
plt.xlabel('SHAP Value')
adjust_plot(title, False)
plt.savefig(f"{save_path}_feature_importance.svg", dpi=300)
plt.show()
shap.dependence_plot('rank(0)', shap_values[0], samples, interaction_index='rank(1)', show=False)
adjust_plot(title, True)
plt.savefig(f"{save_path}_dependence.svg", dpi=300)
plt.show()
titles = ['Logistic Regression', 'Neural Network', 'Random Forest', 'Support Vector Machine']
model_paths = os.listdir('models')
index = 0
for model_path in model_paths:
if '.h5' in model_path:
pass
else:
model = load(f'models/{model_path}')
print(model_path)
shap_feature_importance(features, model, titles[index], f"images/{model_path.split('.')[0]}")
index += 1
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Appendix E
Test
import os
import numpy as np
import pandas as pd
import plotly.figure_factory as ff
import plotly.graph_objects as go
import matplotlib.pyplot as plt
import shap
from joblib import load
from tensorflow.keras.models import load_model
from featurize import generate_descriptors, generate_fingerprints, extract_smiles, extract_smile_structures
shap.initjs()
import warnings
warnings.filterwarnings('ignore')
test_set = pd.read_csv('data/fda_test.csv', low_memory=False)
mordred_features = generate_descriptors(test_set.smile.to_list())
fingerprints = generate_fingerprints(test_set.smile)
test_set = pd.concat([test_set, mordred_features, fingerprints], axis=1)
features = test_set.drop(['name', 'smile', 'type'], axis=1).astype(float)
smile_features = extract_smiles(test_set.smile, max_length=250).astype(float)
smile_structure = extract_smile_structures(test_set.smile, resolution=100, scale=(-15, 15)).astype(float)
meta = test_set[['name', 'type']]
def image_plot(shap_values, labels, figsize):
fig, axes = plt.subplots(nrows=shap_values.shape[0], ncols=1, figsize=figsize)
for row in range(shap_values.shape[0]):
abs_vals = np.abs(shap_values.sum(-1)).flatten()
max_val = np.nanpercentile(abs_vals, 99.9)
axes[row].set_title(labels[row], fontsize=11)
sv = shap_values[row].sum(-1)
im = axes[row].imshow(sv, cmap=shap.plots.colors.red_transparent_blue, vmin=-max_val, vmax=max_val)
for label in (axes[row].get_xticklabels() + axes[row].get_yticklabels()):
label.set_fontsize(8)
fig.subplots_adjust(wspace=0, hspace=0.3)
cb = fig.colorbar(im, ax=np.ravel(axes).tolist(), label="SHAP value", orientation="horizontal",
aspect=figsize[0]/0.2, pad=0.08)
cb.ax.xaxis.label.set_fontsize(10)
for label in (cb.ax.get_xticklabels()):
label.set_fontsize(8)
cb.outline.set_visible(False)
def plot_radar(values_best, values_worse, categories):
fig = go.Figure()
fig.add_trace(go.Scatterpolar(r=values_best, theta=categories, fill='toself', name='Best Prediction'))
fig.add_trace(go.Scatterpolar(r=values_worse, theta=categories, fill='toself', name='Worse Prediction'))
fig.update_layout(showlegend=True, autosize=False, width=500, height=500)
fig.show()
model_paths = os.listdir('models')
results = np.ndarray((meta.shape[0] * len(model_paths), 4), dtype=object)
for model_index, model_path in enumerate(model_paths):
print(model_path)
if '.h5' in model_path:
model = load_model(f'models/{model_path}')

93

if '2d' in model_path:
predictions = model.predict_proba(smile_structure)[:, 0]
sorted_indices = np.argsort(predictions, axis=0)
index = [sorted_indices[-1], sorted_indices[1]]
explainer = shap.GradientExplainer(model, smile_structure)
shap_values = explainer.shap_values(smile_structure)
plt.figure(figsize=(2.5, 2.5))
plt.matshow(np.amax(smile_structure[index[0],:,:,:], 2), cmap=plt.cm.gray_r, fignum=1)
plt.savefig(f"images/example_structure_1.svg", dpi=300)
plt.figure(figsize=(2.5, 2.5))
plt.matshow(np.amax(smile_structure[index[1],:,:,:], 2), cmap=plt.cm.gray_r, fignum=2)
plt.savefig(f"images/example_structure_2.svg", dpi=300)
image_plot(shap_values[0][index], meta.name[index].values, figsize=(3,8))
plt.savefig(f"images/2d_shap.svg", dpi=300)
plt.show()
else:
predictions = model.predict_proba(smile_features)[:, 0]
else:
model = load(f'models/{model_path}')
predictions = model.predict_proba(features)[:, 0]
sorted_indices = np.argsort(predictions, axis=0)
index = [sorted_indices[-1], sorted_indices[1]]
explainer = shap.KernelExplainer(model.predict_proba, features)
shap_values = explainer.shap_values(features, nsamples=50)
best = True
for i in index:
print(meta.name[i])
shap.force_plot(explainer.expected_value[0], shap_values[0][i,:], features.iloc[i,:].values,
list(features.columns.astype(str)), matplotlib=True, show=False, figsize=(20, 3.5), text_rotation=10)
plt.title(meta.name[i], fontsize=12)
plt.tight_layout()
plt.savefig(f"images/{model_path.split('.')[0]}_force_{'best' if best else 'worst'}.svg", dpi=300)
plt.show()
best = False
for pred_index, pred in enumerate(predictions):
index = pred_index + (meta.shape[0] * model_index)
results[index, :] = [meta.iloc[pred_index, 0], meta.iloc[pred_index, 1], model_path.split('-')[0], pred]
results = pd.DataFrame(results, columns=['name', 'type', 'model', 'inhibitor_conf'])
heatmap = None
for strength in ['strong', 'moderate', 'weak']:
temp = results[results.type == strength]
temp = temp.pivot(index='name', columns='model', values='inhibitor_conf').reset_index()
temp['name'] = temp.name + ' [' + strength + ']'
heatmap = pd.concat([heatmap, temp])
plt.figure(figsize=(6, 6))
plt.rcParams.update({'font.size': 7})
x = ['CNN Structure', 'CNN SMILE', 'LR', 'NN', 'RF', 'SVM']
y = heatmap['name'].to_list()
z = heatmap.values[:, 1:].astype(float)
im = plt.imshow(z, aspect='auto')
plt.xticks(np.arange(len(x)), x)
plt.yticks(np.arange(len(y)), y)
for i in range(len(y)):
for j in range(len(x)):
text = plt.text(j, i, round(z[i, j], 2), ha="center", va="center", color="w")
plt.tight_layout()
plt.savefig(f"images/fda_test.svg", dpi=300)
plt.show()
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